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Abstract
The main goal of this thesis was to obtain fully quantifying perfusion parameters from both DSC (Dy-
namic Susceptibility Contrast) and DCE (Dynamic Contrast Enhancement) techniques through usage of
only one perfusion sequence – GESE EPIK (Gradient-echo, Spin-echo Echo-Planar Imaging with Key-
hole). For this, twenty-two patients with a possible brain tumor were recruited for this study, and each
patient was scanned at a hybrid PET-MR 3T scanner. Firstly, T1-mapping data was acquired through
a sequence of Inversion-Recovery EPIK. The contrast agent was then injected into the patient and per-
fusion images were acquired using the GESE EPIK sequence. Simultaneously, 18F-FET images were
acquired which allowed the exclusion of patients who did not have any brain tumor.
After the images were acquired, they were analyzed and the parameters were calculated. For starters, the
information regarding the changes in T2 and T2*, already inherent to the data acquired, was analyzed.
The curve of the MR signal was converted to the concentration curve. This curve was calculated using
two different equations. With the calculated concentration curve, the DSC parameters were calculated.
As expected, in areas affected by a tumor, there was an increase in vascularization due to angiogenesis.
It was also observed, by comparison of the two methods used to calculate the concentration curves, that
the non-removal of the leakage effects induced an unreal increase in the calculated parameters.
In order to obtain images related to variations of T1 for DCE quantification, the images acquired were
extrapolated to a echo time equal to zero. To these extrapolated images, the values obtained from the
T1-mapping prior to the contrast’s injection were subtracted in order to obtain the concentration curve.
A method that used the extrapolated images to obtain an initial T1-mapping was also tested, in order to
avoid the need to implement the extra sequence for that purpose. The Tofts kinetic model was applied
in both methods, allowing the calculation of DCE parameters. In both applied methods, the results ob-
tained were very similar, indicating the possibility of non-acquisition of the extra sequence if there are
time constraints. However, not all parameters behaved as expected and a more detailed investigation of
the literature was carried out. It is concluded that some parameters do not have a clear description and
cannot characterize human physiology and be used in the study of pathologies.
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In conclusion, the initial goal of this thesis to obtain quantitative parameters DSC and DCE perfusion
techniques, using only a single contrast sequence, was achieved with success. The need to remove leak-
age effects, which increased the calculated values and the tumor area, was also verified. However, some
inconsistencies in the parameters’ interpretation were registered in the available literature. These incon-
sistencies had repercussions in some values obtained, whose interpretation was impossible, despite being
in agreement with the literature. In addition, a method has been tested which further eliminates the need
to acquire T1-mapping data prior to the contrast’s injection through an additional sequence. Although not
an objective of this thesis, it was not possible to relate the perfusion parameters to the degree of tumor
severity.
Key-words: MR-PET; Perfusion MRI; GESE-EPIK; DSC; DCE.
v
Resumo
Ressonância magnética de perfusão é um termo utilizado para se referir a uma variedade de técnicas de
ressonância que permitem obter informação relativa ao grau de vascularização dos tecidos examinados.
É baseada no princípio de Fick que define que o fluxo de sangue a um órgão pode ser calculado se for do
nosso conhecimento a quantidade de agente marcador que o órgão examinado absorve, recebe e expele.
Este agente marcador pode ser inerente ao próprio corpo ou ser injetado. Se for injetado é tipicamente
referido como agente de contraste e trata-se de um componente químico à base de Gadolínio. As técnicas
que necessitam de injeção deste contraste são DCE e DSC.
DSC, um acrónimo inglês de Dynamic Contrast Susceptibility, utiliza métodos de rápida aquisição de
imagens para delinear o movimento do agente de contraste na circulação sanguínea do órgão de interesse,
após injeção. É uma técnica dependente da magnetização transversal, T2 ou T2*, e, após aquisição das
imagens, um modelo cinético é aplicado de forma a se obter parâmetros caracterizantes da perfusão dos
tecidos. Desses parâmetros, no caso do volume de interesse ser o cérebro, destaca-se o volume sanguíneo
cerebral (CBV, acrónimo inglês de Cerebral Blood Volume), o fluxo sanguíneo cerebral (CBF, acrónimo
inglês de Cerebral Blood Flow) e o rácio entre eles (MTT, acrónimo inglês de Mean Transit Time). Estes
parâmetros estão intimamente relacionados com a presença de tumores, sendo identificativos dessa pa-
tologia dado que zonas afetadas por gliomas tendem a registar um aumento anormal da vascularização
por presença dessa mesma patologia.
Semelhantemente, DCE, acrónimo inglês de Dynamic contrast enhancment, avalia a absorção de con-
traste pelo tecido, através da evolução da magnetização longitudinal, T1. Nesta técnica, para além da
aquisição de dados após injeção do contraste, é necessário adquirir uma imagem anatómica informativa
dos valores da magnetização longitudinal prévia à injeção da substância marcadora, denominado de T1-
mapping. Esta aquisição extra permite o cálculo de parâmetros quantificativos de perfusão do tecido,
que, de outra forma, seriam apenas relativos. Os parâmetros calculados dependem ainda do modelo
cinético aplicado aos dados adquiridos.
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Dado que ambas as técnicas de ressonância magnética de perfusão fornecem informações comple-
mentares, foi do interesse de medicina adotar o uso de uma sequência de ressonância magnética que
adquirisse informação tanto da magnetização longitudinal como da transversal. Uma sequência que per-
mitisse tal aquisição foi desenvolvida no Forschungzentrum Jülich. Esta sequência denominada GESE
explora as vantagens de aquisição da técnica de imagem Echo-planar Imaging with Keylohe (EPIK).
Esta sequência permite obter imagens relativas às alterações da magnetização transversal, ao longo do
tempo, e permite a extrapolação de imagens relativas às alterações da magnetização longitudinal devido
ao número e tipo de ecos que a compõem. Desta forma, é possível obter imagens relativas a ambas as
técnicas DSC e DCE. Esta dissertação tem como objetivo obter parametros quantitativos das duas técni-
cas de perfusão utilizando uma única sequência - GESE EPIK.
Para este estudo foram recrutados vinte e dois pacientes com possível presença de tumor cerebral, que,
a pedido médico, necessitavam de um exame de 18F-FET . Cada paciente foi injectado com uma dose
de 0.1 mmol/kg de Gd-DTPA por peso corporal. As medições foram realizadas no scanner híbrido de
MR-PET de 3T. O T1-mapping foi adquirido em primeiro lugar através de uma sequência de Inversion-
Recovery EPIK. Seguidamente, o agente de contraste foi injectado no paciente e as imagens de perfusão
foram adquiridas usando a sequência GESE EPIK. Simultaneamente, foram adquiridas imagens de 18F-
FET que permitiram a exclusão de pacientes que afinal não apresentavam tumores cerebrais.
Após aquisição das imagens, estas foram analisadas e os parâmetros calculados. Iniciou-se pela análise
da informação relativa a T2 e T2*, já inerentes aos próprios dados adquiridos. A curva do sinal de RM
foi convertida na curva de concentração. Esta curva foi calculada utilizando duas equações distintas de
forma a permitir a verificação da influência da passagem do contraste para fora da corrente sanguínea no
cálculo da curva. Foi calculada ainda a curva que representa a fornecimento do agente de contraste ao
tecido estudado, por meios de um método automatizado desenvolvido no centro de investigação. Neste
método, são procuradas as curvas com maior amplitude de sinal, ordenadas por ordem crescente de am-
plitude e com as últimas cinco (pode se optar por outro número) é calculada uma curva média. Esta curva
é necessária para o cálculo dos parâmetros e é denominada por AIF (acrónimo inglês de Arterial Input
Function). Com a curva de concentração calculada e a AIF, os parâmetros já referidos foram calculados.
Como seria de se esperar, em zonas afetadas por um tumor, houve registo de um aumento da vasculariza-
ção, devido à angiogénese. Observou-se ainda, por comparação dos dois métodos de cálculo das curvas
de concentração, que a não remoção dos efeitos da passagem do contraste dos vasos para o tecido induz
um acréscimo irreal nos parâmetros calculados.
De forma a obter imagens relativas às variações de T1, as imagens obtidas foram extrapoladas para um
tempo anterior à aquisição de forma a que projetassem informação da magnetização longitudinal. A estas
imagens extrapoladas foram subtraídos os valores obtidos do T1-mapping de forma a se obter uma curva
de concentrações não relativas. Foi ainda testado um método que utilizava as imagens extrapoladas para
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obter um T1-mapping inicial de forma a evitar a necessidade da implementação da sequência extra para o
efeito. Foi aplicado o modelo cinético de Tofts, explicativo da fisiologia inerente, em ambos os métodos
utilizados, possibilitando o cálculo dos parâmetros Ktrans e Kep. Estes parâmetros são representativos do
fluxo de substâncias entre os vasos sanguíneos e o plasma intercelular, ou seja, caracterizam a perme-
abilidade do tecido. Em ambos os métodos aplicados, os resultados obtidos foram muito semelhantes,
indicando a possibilidade de não aquisição da sequência extra caso haja limitações do tempo de exame.
No entanto, dos dois parâmetros obtidos, apenas o parâmetro Ktrans se comportou como seria de esperar,
tendo valores maiores em regiões tumorais. Já o parâmetro Kep comportou-se de forma irregular, sendo
que uma investigação mais aprofundada à literatura foi realizada e concluiu-se que este parâmetro não
tem uma descrição consensual, não podendo assim ser caracterizante da fisiologia humana e utilizado
com rigor no estudo de patologias.
Apesar de não ser um objetivo inicial, pensou-se em analisar os valores dos parâmetros e compará-los
com a gravidade do tumor, de forma a perceber se havia alguma relação que permitisse a classificação
do glioma sem necessidade de uma biopsia. No entanto, tal comparação não foi possível dado que não
havia informação prévia do grau de severidade do tumor de cada paciente.
Em conclusão, o objetivo inicial desta tese de obter parâmetros quantitativos das duas técnicas de per-
fusão utilizando apenas uma única sequência de contraste foi atingido com algum sucesso. Comprovou-
se ainda a necessidade de remoção dos efeitos de passagem do contraste da corrente sanguínea para os
tecidos, que incrementavam os valores calculados e a área tumoral. No entanto, registou-se uma incon-
sistência na interpretação dos parâmetros em várias literaturas, provenientes da aplicação de modelos
cinéticos cujos parâmetros foram introduzidos sem bases reais na fisiologia ou com incoerências na sua
explicação. Estas inconsistências tiveram repercussões nalguns valores obtidos, cuja interpretação foi im-
possível, ainda que estivessem de acordo com a literatura. De realçar que a mesma literatura raramente
interpretava os valores obtidos ou, quando o fazia, cada estudo tinha a sua interpretação, não havendo
uma descrição fisiológica que justificasse os valores obtidos. Adicionalmente, testou-se um método que
permite ainda excluir a aquisição de um T1-mapping prévio à injeção do contraste, removendo a ne-
cessidade de uma sequência adicional e diminuindo o tempo de exame. Através da extrapolação do
T1-mapping, o tempo de exame diminui, o que pode ser essencial para certos pacientes. Ainda que não
fosse um objetivo desta tese, não se conseguiu relacionar os parâmetros de perfusão com o grau de sev-
eridade tumoral. De forma a confirmar a realidade destes valores de perfusão sugeriu-se a criação de um
phantoma de perfusão.
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Imaging of brain hemodynamics and cerebral vascular parameters have been assessed by many imaging
modalities such as computed tomography (CT) ([1], [2]), positron emission tomography (PET) ([3], [4])
and single photon emission computed tomography (SPECT) ([5]), among others. Every method has its
advantages and disadvantages. For example, in CT there is high anatomic resolution, but limited im-
mediate cortical enhancement following contrast injection which lessens its clinical usage. PET scans
are superior to all other metabolic imaging methods in terms of resolution and imaging speed. However,
some of the used radioisotopes have short half-lives and, therefore, decay rapidly, making it quite difficult
to be used in a large number of institutions and limiting the exams’ duration [6]. With the development
of “ultra-fast” MR imaging techniques, a dynamic assessment of brain hemodynamics became possible
in MRI, also known as perfusion MRI.
Perfusion MRI is a term used to refer to a variety of MRI techniques which assess the vascularization
of the imaged tissue along with the delivery of oxygen and nutrients. In other words, perfusion MRI
techniques trace the blood in order to give insight of the region vascularization. Arterial spin labeling
is a perfusion technique in which contrast injection is not required. Meanwhile, for DSC and DCE an
exogenous substance must be injected.
DCE and DSC techniques both require the injection of a contrast agent, typically Gadolinium based.
While the contrast agent passes through the vasculature, it produces changes in the MR signal intensity
that are then measured and used to study tissues’ properties. Both techniques are used for brain tumor
diagnosis and characterization. Several studies have even addressed the possibility of using derived per-
fusion parameters to grade the tumors ([7], [8], [9]).
Dynamic Susceptibility Contrast, DSC, is a technique usually based on a T2- or T2*-weighted imaging
sequence, with two-dimensional (2D) or three-dimensional (3D) dynamic acquisition [10]. The scan
protocol can consist of a gradient-echo (GE) acquisition or a spin-echo (SE) acquisition. GE sequences
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are more prone to static field inhomogeneities which result in signal losses. Meanwhile SE acquisitions
compensate for the field inhomogeneities with a refocusing pulse.
Dynamic Contrast Enhancement, DCE, is a technique usually scanned with a T1-weighted imaging se-
quence with 2D or 3D dynamic acquisition. GE measurements are sensitive to all vessel sizes, but SE
measurements are more sensitive to small vessels. For quantitative DCE-MRI, a pre-contrast mapping of
T1 is often performed, or in clinical practice, in order to save scanning time, a constant baseline T1 value
is often used. For this, the most used sequences are inversion-recovery spin-echo sequence (IR-SE) or,
alternatively, IR-SE with echo planar imaging (EPI) [11].
The parametric images extracted from both DSC and DCE are relevant to characterize tumors [7]. How-
ever, the clinical methodology used to acquire those parametric images is based on two independent
pulse sequences – one for DSC and one for DCE ([8], [12]) – where each has its associated drawbacks.
These sequences are single-shot GE EPI and spoiled GE, respectively. On one hand, single-shot GE EPI,
for DSC, suffers from errors due to CA leakage, which often addressed with a pre-load injection prior to
the actual measurement, increasing measurement time and amount of injected contrast agent [9]. This is
an approach that reduces uncertainties but does not completely eliminate them [13]. On the other hand,
T1-weighted imaging using spoiled GE, used for DCE, requires a balanced trade-off between temporal
resolution and brain coverage [8].
In order to overcome the need for two independent sequences and address some of the associated draw-
backs, several techniques have been suggested to mitigate or eliminate all drawbacks. Among them were
correction algorithms [14], a pre-dosage with a small amount of Gadolinium-based contrast agent [15],
MRI pulse sequences that use excitation pulses with lower flip angles, or multi-echo GE perfusion MRI
methods in which tracer concentrations are based on absolute R2*(t) instead of its relative changes [16].
A method using a refocusing pulse after the first two echoes to obtain SE contrast has been proposed
[17] and is called Spin and Gradient Echo (SAGE) or Gradient-echo, Spin-echo (GESE) DSC method.
GESE DSC has been successfully demonstrated in humans to image different organs, and in small ani-
mals. However, this approach also has the usual limitations such as susceptibility artefacts and geometric
distortions resulting from the single-shot EPI readout. Therefore, an alternative method for GESE DSC
using EPIK was proposed in [18]. This method showed improvements in the perfusion measurements,
having a reasonable trade-off between spatial/temporal resolution and brain coverage. By combining the
first two echoes and extrapolation to TE=0, semi-quantitative T1-based data related to DCE methods can
be obtained.
This sequence, however, like the others before, only allows for semi-quantitative analyses of DCE-based
parameters. To fully quantify the DCE-based parameters, a T1 map prior to contrast injection is required,
as already referred. This remains as one of the current challenges to completely overcome the need for
two independent imaging sequences in brain perfusion imaging.
1.2 Thesis’ Objectives and Outline
This master thesis project has two goals: i) to use the sequence SAGE EPIK with 5 echoes to acquire both
DSC and DCE data and ii) to quantify both data-sets and obtain perfusion parameters specific to each
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technique. To fully quantify DCE parameters, T1-mapping previous to contrast injection is required.
Therefore an additional sequence for this purpose was added and used. Although not a initial goal, a
method for extrapolating the T1-mapping was also tested in order to address the future possibility of only
requiring the SAGE EPIK sequence.
This thesis is organized in seven chapters described below. The present Chapter 1 introduces the context,
motivation and general organization of the work.
Chapter 2 introduces some relevant theoretic concepts for this work. MR physics, imaging principles
and used hardware are firstly introduced, followed by MR sequences most relevant for this project. A
small section in hybrid imaging was also included since all data was acquired in a PET-MR scanner and
the PET images were used to filter patients without tumor from the data to be used for this project.
In Chapter 3, a brief introduction to brain tumors, particularly their severeness and grading are addressed.
Chapter 4 describes the two studied perfusion techniques - DCE and DSC - introducing the concepts and
the methods used for the analyses of the acquired data. These analyses methods include both fully
quantifying methods and non-quantifying methods for better understanding of the relevance of the first
ones.
In Chapter 5, materials and methods developed in this dissertation are described. Patients’ information,
MRI and PET acquisitions along with MRI data analyses are addressed. This includes both perfusion
techniques parameter derivation.
Chapter 6 presents the results obtained in this work from the methodologies explained in the previous
chapter. The results are also interpreted and discussed in this chapter.
Finally, in Chapter 7, final conclusions are drawn and possible error sources are identified. Whether the
goals were reached and what future work ought to be performed are also included in this final chapter.
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Magnetic resonance imaging (MRI) is a versatile imaging modality that is widely used in clinical prac-
tice for the diagnosis and evaluation of a broad range of disorders, including cancer [19][20]. MRI can
non-invasively, and without the hazard of ionizing radiation, produce high resolution images in multiple
(arbitrary) planes of the interior of the body. There are several types of MR images, some of which
are exquisitely sensitive to subtle changes within soft tissues. Typically, MRI uses magnetic fields and
radio frequency energy to acquire signals (that are then used to construct images) from hydrogen nuclei,
contained mainly in tissue water. The contrast depicted in MR images is typically due to variations from
tissue to tissue in the density of hydrogen nuclei, and/or in other MR properties such as the relaxation
times T1 and T2, which largely depend on the macromolecular composition of tissues. In many patholo-
gies, the intrinsic contrast between soft tissues is sufficiently great that often contrast agents are not
needed or used with MRI. Nonetheless, to derive special contrasts for a particular MR application (e.g.
angiography and perfusion), the use of exogenous contrast has been proven to be safe in many clinical
imaging procedures [21].
2.1 Magnetic Resonance Physics
2.1.1 Nuclear Spin and Precession
The structure of an atom is an essential component of the MR experiment. For MRI, a particular type of
nucleus is selected and its distribution throughout the body is evaluated. Hydrogen is the most commonly
imaged element, not only due to its abundance in the body, but also because it gives the strongest MRI
signal.
The hydrogen atom is a single proton which is not stationary, but actually spins around an axis as shown
in Figure 2.1. This non-stationary property of these atoms is the source of the MRI signal. The spinning
property of atomic and subatomic particles is known as spin or spin angular momentum. Although it is
described as spin, the particle is not actually spinning or rotating. In fact, its rotational axis is constantly
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changing, or in other words, its nucleus are precessing. The magnitude of spin is quantised, meaning
that it can only take on a set of limited discrete values.
Figure 2.1: Classical representation of a proton precessing in a magnetic field of magnitude B0. Adapted from [22].
Typically, in the human body, each of the hydrogen protons will have its spin axis orientated at random
and their individual magnetic fields tend to cancel each other out. Their magnetic momentum, µ , and
angular momentum, L, are related by:
µ = γL (2.1)
, where γ is the gyro-magnetic ratio which is nuclei specific. In the presence of a static external magnetic
field B0, they preferably align themselves with the direction of the field. Their precession frequency will
now be calculated by
wL = γB0 (2.2)
, the so called, Larmor frequency.
2.1.2 Bloch’s Equations
The Bloch’s equations are a set of equations that describe the behaviour of the macroscopic magnetiza-
tion, M(t), in the presence of an external time-dependent magnetic field.
They were firstly introduced by Felix Bloch in 1964, whose name was given to the equation in honor
of his discovery [23]. Bloch began with the assumption that the existent nuclei in a sample could be
represented by a single vector, M(t), where this vector also possesses spin angular momentum. When
this macroscopic sample is placed in a external magnetic field, the net magnetization will experience a
torque force which can be described by Equation 2.3.
dM(t)
d(t)
= γ [M(t)×B(t)] (2.3)
Further explanation of the Bloch equations and the origin of the MRI signal are devised in the two
following subsections: excitation and relaxation.
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2.1.2.1 Excitation
When an oscillating system, with its own frequency, is subjected to an external periodic stimulus and, if
the forcing frequency equals its own natural frequency, the outcome will be its best possible - excitation.
This is called the resonance phenomenon. This is the origin of the MRI signal; when a radio pulse
with the Larmor frequency is applied, the protons resonate, absorb the energy and can then "flip" to high
energy state. In addition, they are also forced to process in phase with the pulse.
When in an external magnetic field, the protons reach their magnetization within a few seconds and
remain at that level unless they are disturbed by a change in the field or by pulses of radio-frequency
(RF) energy. This radio frequency pulse is commonly referred to as an excitation pulse and typically
contain a narrow range of or bandwidth of frequencies around a central frequency. During the pulse, the
protons, as explained, absorb a portion of this energy at a particular frequency which is proportional to
the B0. Following the pulse, the protons re-emit the energy of the same frequency.
Considering M0 the initial state of the representative vector M(t). The energy applied is an RF pulse
with central frequency WRF and orientation perpendicular to B0, often addressed as B1. The difference
in orientation allows energy to be transferred to the protons. When wRF = wL, the RF energy is absorbed
which causes M0 to rotate away from its equilibrium orientation producing a transverse magnetic field.
2.1.2.2 Relaxation
After the applied RF, the excited protons will return to their original orientation in the B0 field, by giving
up the acquired extra energy, in a process known as relaxation.
While the system returns to the equilibrium state, an increase of longitudinal magnetization occurs,
simultaneous to a decrease of the transverse magnetization.
The longitudinal magnetic field increases to its original state, recovering by energy transference from
the protons to the surrounding macro-molecules. This energy exchange process is called spin-lattice
interaction. This recovery is exponential and, when a 90◦ is applied, is characterized by a longitudinal
relaxation time T1 and Equation 2.4.
Mz(t) = M0z (1− e−t/T1) (2.4)
The behaviour of longitudinal magnetization recovery Mz is depicted in Figure 2.2 (left).
The transverse relaxation is the mechanism which results in a decay or decrease of the transverse mag-
netization, Mxy. The protons become out of phase again by exchanging energy with the surrounding
protons, a spin-spin interaction. This loss of phase, following the application of a 90◦ pulse, is charac-
terized by Equation 2.5.
Mxy(t) = M0xye
−t/T2 (2.5)
,where T2 is the transverse relaxation time constant, generally much shorter than T1. The behaviour of
recovery Mxy is depicted in Figure 2.2 (right).
The transverse relaxation time constant, T2 relaxation, also depends on fluctuations of the z-component
and consequently T2 is always less or equal to T1.
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Figure 2.2: Longitudinal (left) and transverse(right) relaxation times, Adapted from [24].
However, in any real MR experiment, the transverse magnetization decays faster than what would be
predicted by natural atomic and molecular mechanisms. This decay rate is commonly denoted as T2*
("T2-star"). T2* can be considered an "observed" or "effective" T2, whereas the first T2 can be consid-
ered the "natural" or "true" T2 of the tissue being imaged. T2* is always less than or equal to T2. T2*
relaxation refers to the decay of transverse magnetization, Mxy caused by a combination of spin-spin
relaxation and magnetic field inhomogeneity. Typically these field inhomogeneities are removed by the
application of a 180◦, but some MRI techniques make use of this decay for T2* imaging, as shown in
Figure 2.3 [25].
Figure 2.3: Echoes and echo time. Echo formation with a combination of a 90º and 180º RF pulses. Adapted from [26].
In summary, in the decay of the transverse magnetization two factors contribute to the loss of phase
coherence: the natural loss of phase coherence and the B0 inhomogeneities, respectively the "true" T2
and T2’, respectively. The combination of both factors results in the transverse magnetization decay










The ease with which the adjacent atoms can absorb the surplus energy depends on the exact nature of
the tissue and its physiological characteristics, allowing the differentiating tissue types. In other words,




Nuclear Magnetic Resonance was a technique mainly used for spectroscopy, to study the chemical prop-
erties of materials and samples. In 1973, P. Lauterbur introduced the concept of spatial encoding using
magnetic field gradients and added it to NMR which made MRI possible [27]. A. Kumar then used the
magnetic gradients to obtain 2D Fourier encoded images [28], and P. Mansfield, following the developed
work, acquired the first in vivo MR images [29].
The described works led to a new medical imaging technique - Magnetic Resonance Imaging (MRI).
In other words, the MR signal originates from the induction of a small electrical current in the receiver
coil by the precession of the net magnetization during resonance. This is a manifestation of Faraday’s
Induction Law, where a changing magnetic field induces a voltage in the nearby conductor. The time-
dependent force induced in the RF coil by the change in magnetization in the Mxy plane carries the NMR
information where every spin’s contribution to the free induction decay (FID) is dependent on its loca-
tion. In the following sections, the basic imaging principles, involving the processes taking place in the
generation of the final MRI signal, are introduced.
2.2.1 Slice selection
In 2D-MRI, first a plane of interest in the body is selected for imaging. Knowing that the Larmor fre-
quency of the protons is directly proportional to the applied steady external magnetic field B0, it is
possible to excite only a specific region of the total imaging volume. Equation 2.2 expresses this rela-
tionship, where wL can be replaced by 2π fL, in order to lie within in the radio-frequency range.
Figure 2.4: Slice excitation and relation between excited frequencies and slice thickness. Adapted from [30].
In other words, by changing the resonating frequecny in the corresponding section of the body, the pro-
tons in this area will resonance at a different frequency. If we apply a RF pulse of this specific frequency,
only these protons in the regions will resonate, thus providing a way to identify the slice of interest.
The slice selection involves, then, a localized variation in the value of the external field, which is achieved
by the usage of gradient field coils. By applying a linear magnetic field in the direction of choice, nor-
mally z, the amplitude of the magnetic field would vary in this direction. In more detail, two steps are
required to uniquely excite a slice. Firstly, a slice-select gradient (Gz) is imposed along an axis perpen-
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dicular to the plane of the desired slice, normally z, resulting in a linear variation of potential resonance
frequencies in that direction. Secondly, a specially tailored RF-pulse is simultaneously applied, whose
frequency components match the narrow range of frequencies contained in the desired slice. The narrow
range of frequencies is defined by the position of the slice (z) and its thickness (∆z), which correspond,
respectively, to the central frequency (Fc) calculated by Equation 2.7 and the range of frequencies around
it, ∆w, calculated similarly by replacing Fc with ∆f and z with ∆z.
Fc = γ(B0 + zGz) (2.7)
The combination of both steps ensures that only protons within the chosen slice are excited.
2.2.2 Frequency and Phase encoding
Slice selection does not differentiate between protons within each slice. Two additional gradients are
usually applied in order to encode the spins in the slice.
The measured slide is composed of a number of x columns and y rows, adding up to a total of x·y
individual elements, called pixels.
One of the gradient fields establishes a specific frequency for one of the other remaining coordinates,
usually the x-axis, similarly to the slice selection gradient. This gradient is commonly referred to as
the frequency encoding grading, Gx. The other gradient modifies the phase of the precessing protons,
in the remaining direction, the y-axis. This gradient is typically referred to as the phase encoding
gradient, Gy. Both gradients have identical properties, but are applied in different directions, at different
times. However, one must bear in mind that the x- and y-gradients do not skew or shear the main
field transversely. They simply provide augmentation in the z-direction to the B0 field as a function
of anterior-posterior location in the gantry. The x- and y-gradients (ideally, at least) do not produce
components perpendicular to B0.
With the 3 gradients (Gx, Gy, Gz), the pixels can now be localized in all three directions (x, y, z). Other
properties of the MR also aid in the localization of the MR signal, for example the differences in signal
timing and the distance to the receiver coils. The adequate usage of this imaging strategies allows the
acquisition of faster and better MRI images.
2.2.3 K-space and Image Reconstruction
The concept of k-space was first applied in magnetic resonance imaging in 1983 by Ljunggren [31] and
Twieg [32].
As described previously, the MR signal results from current induction by precession of the net magne-
tization after excitation through an RF-pulse. The signal is detected by the receiver coils and can be
represented by a vector with both real (Re) and imaginary (Im) components, or alternatively represented
as a complex number like in Equation 2.8.
Signal = Re+ iIm (2.8)
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The changes in the signal are stored in a temporal matrix, referred to as the k-space which codifies the
image in frequency domain, rather than time domain. By applying a Fourier Transform (FT) on the k-
space, the image reconstruction can be performed. To put it in simpler terms, the k-space can be defined
as the space of spatial frequencies and is the inverse space of the physical coordinates system (x, y). The
spatial frequency variables kx and ky are related to the time on gradient variables. Therefore, k-space
data is just the MRI time domain data where the variables (t, (Gx,Gy, Gz)) were replaced by (kx, ky)
[32].
The data to fill the k-space can be acquired in any order. While the Cartesian methods used to be the
most dominant, nowadays, spiral or radially oriented trajectories are also widely used [33], [34].
2.3 Instrumentation and Equipment
An MRI scanner is made up of four main components: the magnet, the gradient coils, the radio-frequency
coils (transmitter and receiver), and the computer. In this section the general design and main functions
of these components are discussed, with the exception of the computer as its functions are obvious:
operator interface, in addition to data storage and processing.
Figure 2.5: Schematic representation of the main components in a MRI system. Adapted from [35].
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2.3.1 Magnet
Perhaps the most important component of the MRI scanner, the magnet, is responsible for generating the
main static field, B0 while assuring its homogeneity. The strength of the magnet is measured in teslas, T.
Clinical magnets generally have a field strength in the range 0.1–3.0 T, with research systems available
up to 9.4 T for human use and 21 T for animal systems.
The magnet can be categorized in three types of magnets: permanent, resistive or superconducting mag-
nets. The first two were used in early MR experiments at lower fields. Permanent magnets are generally
made from ferromagnetic materials and can only provide low field strengths (usually less than 0.4 T).
Though very inexpensive to maintain, they cannot be switched off and they are of limited precision
and stability. Resistive magnets are made of cheaper materials and generate magnetic fields of medium
strength, but involve higher maintenance costs since they dissipate a lot of energy.
Nowadays, due to the need of higher field strengths, superconducting magnets are widely preferred.
These magnets are generally made of a niobium-titanium alloy which is cooled to even inferior values
than its critical temperature with liquid helium (around 10K) in order to, constantly, offer zero electrical
resistance. Consequently, these magnets need to be refilled with helium at frequent time periods. An
electromagnet constructed with superconductors can have extremely high field strengths and with very
high stability, causing them to be the most sought after.
When the MR scanner is placed in the hospital or clinic, its main magnetic field is far from being ho-
mogeneous enough to be used for scanning. The shim coils are a set of resistive coils which are placed
inside the magnet and are able to produce field corrections.
2.3.2 Gradient Coils
As referred in Section 2.2.2, gradient coils are responsible for spatially encoding the position of the
protons by varying the magnetic field linearly across the imaging volume. Gradient coils are usually
resistive electromagnets powered by sophisticated amplifiers which permit rapid and precise adjustments
to their field strength and direction. When an electrical current passes through these coils, the main
magnetic field is focally distorted in certain places, creating the desired magnetic field changes.
The performance of the coils is dependent on the gradient strength, linearity, stability, duty cycle and
slew rate times. The slew rate of a gradient system is a measure of how quickly the gradients can be
ramped on or off. In parallel, the performance of the gradient coils influences the sequence design and
scanning time as stronger gradients allow for faster imaging, and, similarly, gradient systems capable
of faster switching can also permit faster scanning. However, gradient performance is limited by safety
concerns over nerve stimulation.
2.3.3 RF Coils
The RF coils generate (transmitter coil) RF pulses and detect (receiver coil) the generated signals es-
sential to the MRI signal’s generation. There is a saying in MRI that goes : "An MR scanner is a coil
within a coil within a coil within a coil...". Although ironic, there is some ground truth in this saying.
Apart from the main magnet and gradient coils, there are also the RF body coil and the patient coils. The
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body coil is responsible for transmitting ( and can also receive) the B1 field, while the patient coils, for
example the head coil, lay closer to the imaged region in order to better receive the signal and increase
its quality. These patient coils can also be referred to as surface coils, as they can be made with different
shapes to better contour the body region which is being imaged.
2.4 MR Sequences
2.4.1 Spin-Echo (SE)
A single radio-frequency pulse generates a free induction decay, however, if another RF pulse is applied,
which refocuses the excited spins, spin echo signals can be produced. In a slice-selective spin-echo (SE)
sequence, the first excitation pulse of 90◦ is applied together with a slice selection gradient to tip the
proton spins into the transverse plane. Since not all spin groups are equal, local microscopic fields may
differ causing some spin groups to gain phase and precess faster. After the RF excitation, a phase gradient
is applied along the y-axis, whose amplitude determines the y-line of the k-space to be filled. The 180◦
RF pulse is then applied together with the same slice selection gradient to flip the spins and make them
rotate back towards coherence. The signal is acquired around echo time (TE), while a readout gradient
along the x-axis is switched on. A schematic overview of a SE sequence is illustrated in Figure 2.6.
Figure 2.6: Schematic of a 2D SE MR sequence. A 90◦ pulse is applied for excitation. At TE/2 a refocusing 180◦ pulse is
applied and at TE the signal is acquired. Adapted from [29].
2.4.2 Gradient-Echo (GE)
As the name implies, in a gradient-echo (GE) sequence, gradients are used to dephase and rephase the
transverse magnetization vector instead of the 180◦ RF pulse. In GE sequence, an RF pulse is applied to
partially flip the net magnetization vector into the transverse plane (flip-angle-α ). The first gradient is
applied to dephase and then a gradient with opposite sign is applied with the same strength but opposite
polarity to the dephasing gradient, to rephase the spins.
A slice-selective GE sequence begins with the application of a RF excitation pulse simultaneously with
the slice selection gradient. When the excitation pulse is turned off, the protons begin to dephase and a
phase encoding gradient is applied along the y-axis. Simultaneously or instantly after, a negative readout
gradient is applied along the x direction in order to induce a faster dephasing of the protons. Thereafter,
a positive readout gradient is applied to rephase the protons at the same time as the echo is measured. A
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schematic overview of a GE sequence is illustrated in Figure 2.7.
Furthermore, in a GE sequence, as the refocusing of spins are purely based on gradients and not on a
180◦ pulse, the local field inhomogeneities, due to susceptibility effects, are not compensated by the
echo. Therefore, the signal is dependent of T2* rather than T2 which leads to T2* -weighted images
instead of T2-weighted images in the SE sequence.
Figure 2.7: Schematic of 2D GE MR sequence. Following the RF excitation pulse, a phase gradient is applied. Immediately
after, a negative readout gradient is applied for faster proton dephasing, followed by a positive readout to rephase the protons
again, while echo is measured. Adapted from [29].
2.4.3 Echo-Planar Imaging (EPI)
Advances in gradient and digital data acquisition technology have made it possible to obtain individual
MR slices in the time frame of 50-100 msec, thus minimizing the effects of patient motion, while aiming
to increase temporal resolution. Generally, the used imaging technique is called echo-planar imaging,
EPI. Although EPI seems to be a rather recent technique, it is one of the oldest as it was first described
by Mansfield in 1977 [29]. However, this technique was prone to severe image distortions. As originally
defined, EPI referred to a sequence in which data from all of k-space for an entire 2D plane was collected
following a single RF-excitation pulse. More recently the term has been expanded to include any rapid
gradient-echo or spin-echo sequence in which k-space is traversed in one or a small number of excita-
tions. In the modern lexicon, these are termed single-shot EPI and multi-shot EPI, respectively.
EPI is an imaging technique where an RF pulse is followed by a strong frequency encoding gradient ap-
plied simultaneously with an intermittent low magnitude phase encoding gradient. A schematic overview
of a EPI sequence is illustrated in Figure 2.8.
An EPI pulse sequence differs from conventional pulse sequences as EPI employs a series of bipolar
readout gradients to generate a train of gradient echoes. With an accompanying phase-encoding gradi-
ent, each gradient is distinctively spatially encoded so that multiple k-space lines can be sampled under
the envelope of a FID or an RF spin echo. EPI uses a gradient-echo train to accelerate data acquisition,
generating images in a considerably shorter time.
This leads to a k-space sparsely filled in with a trajectory represented on Figure 2.9.
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Figure 2.8: Schematic of a 2D EPI MR sequence. An RF pulse is followed by a strong frequency encoding gradient applied
simultaneously with an intermittent low magnitude phase encoding gradient. The data is acquired from [29].
2.4.3.1 Single-shot and Multi-Echo EPI
Regarding the k-space sampling, EPI sequences can be divided into two groups: Single-Shot and Multi-
Shot or also named segmented. The main difference between both sequences is on the k-space acquisi-
tion.
In a single-shot sequence, the entire range of phase encoding steps are acquired [36]. Therefore, the all
k-space data are acquired in only one shot, achieved by generating and reading all of the required echoes
from a single FID as shown in Figure 2.9. However, the image acquisition matrix is typically no larger
than 78x78. Nowadays, single-shot EPI is the most widely available fast imaging sequence on clinical
scanners and facilitates whole-brain coverage at reasonable Signal to Noise Ratio (SNR). Single-shot
can easily be applicable because it does not need specialized gradient amplifiers to perform the required
gradient switching.
In multi-shot sequence, more excitations are needed to acquire the information of one slice. Also, the
range of phase encoding steps is equally divided into several "shots" per slice. Thereby, a subset of read-
out gradient is acquired within each TR and the k-space is acquired in each shot. The shots are repeated
until a full set of data is collected as illustrated in Figure 2.9. This sequence can be applied in diffusion
and perfusion MRI due to the requirement of shorter TE [36].
When comparing multi-shot EPI with single-shot EPI, the first one is less prone to image distortions
[37]. Recent studies have shown that physiological noise originated from respiration increase linearly as
the number of shots increase for a fixed TR in a multi-shot EPI [38].
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Figure 2.9: K-space acquisition for a) single-shot b) multi-shot. Adapted from [39].
Comparisons between single-shot and multi-shot EPI reported that in multi-shot, the SNR is higher than
in single-shot due to the shorter TE and presents less susceptibility artifacts due to shorter readouts.
However, this sequence requires longer TR when compared to single-shot for the same number of slices
and resolution [36].
2.4.3.2 Echo-Planar Imaging with Keyhole (EPIK)
In 1993, several researchers from the Netherlands, proposed using a keyhole method for accelerating
imaging of contrast agent uptake, where one would skip the acquisition of the data normally taken with
strong phase-encoding gradients [39]. This imaging method was proven to be compatible with other
acceleration methods and Shah et al. suggested that when combined with EPI, perhaps the resulting
images would not wield as many distortions. This originated a theoretical EPIK that was then validated at
1.5 T, for 3 T and fMRI [40]. Furthermore, this method, when compared to EPI, showed, not only a higher
temporal resolution and smaller image distortions, but also enhanced characterization of functional areas
[41].
Figure 2.10: K-space acquisition for EPIK. Each k-space trajectory is devided intro three distinct regions: a keyhole region
(Kk) where the all lines are sampled in every measurement; and two sparse regions (Ks) where each measurement acquires only
certain lines. Adapted from [16].
EPIK consists of a multi-shot EPI sequence where keyhole technique is applied. Keyhole techniques are
based on the principle that the information in the high spatial frequencies is relatively little, therefore
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only the low frequencies of an area of the k-space are updated. However, EPIK is not a standard keyhole
technique. In EPIK, the periphery of the k-space, containing high spatial resolution information, is
continually updated, although more sparsely as illustrated in Figure 2.10. When compared with EPI,
with the sharing of the k-space, EPIK acquisition times are shorter, maintaining similar SNR, reducing
susceptibility artifacts and improving spatial resolution.
2.4.4 Look-locker based T1 mapping sequence
Quantitative measurement of T1 relaxation time is of great importance in many applications as its knowl-
edge can be used for the diagnosis of human brain diseases or for optimizing image’s contrast. The
traditional "gold standard" method used for determining tissue T1 was to perform a series of independent
single-point inversion recovery signal measurements at different TI’s. In 1970, Look and Locker rea-
soned that instead of making a single measurement at a fixed TI after inversion, many more data points
could be acquired by sampling a periodic train of rapidly applied constant flip-angle pulses. Rather than
being only one sequence, Look-locker is a method, from which several sequences have been developed.
Echo-planar imaging was incorporated into the inversion recovery LL-based method by interleaving EPI
readouts for eight different slices after an inversion pulse [42]. The sequence was repeated and the slice
order was changed to achieve a range of inversion times for each slice, in a total acquisition time of thirty
seconds [43]. More recently, a LL-based method using EPIK was proposed [44]. A sequence scheme of
this method can be seen in Figure 2.11.
Figure 2.11: Sequence diagram of the Look-Locker method using EPIK. Before the first inversion pulse and data acquisition,
a series of ° preparation pulses are applied to make the longitudinal magnetization in each imaging plane approach a steady
state.Adapted from [44].
2.4.5 SAGE-EPI or GESE-EPI
In order to overcome and address some of the associated drawbacks of gradient-echo and spin-echo se-
quences, several methods were proposed to combine gradient-echo with spin-echo, echo planar imaging
[17]. These new pulse sequences facilitated the simultaneous acquisition of GE and SE data [45]. How-
ever, the MRI pulses sequences used in [17], [45] and [46] have the drawback that they are all sensitive
to T1-shortening effects caused by CA extravasation through the bloodstream. Also, in some previous
studies few echo trains prevented the absolute quantification of R2 and R2* [45].
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With the purpose of overcoming the limitations on the existing sequences that tried to combine SE and
GE, a spin- and gradient-echo echo-planar imaging (SAGE-EPI) MRI pulse sequence was created [17]
also referred as GESE-EPI. In SAGE, a spectral–spatial signal excitation pulse is followed by two EPI
readout trains acquired at echo times TE1 and TE2, a 180◦ refocusing pulse, and three more EPI readouts
(TE3–TE5), with the last readout at TE5= TESE resulting in a SE signal.
The SAGE-EPI pulse sequence is similar to the multi-echo PERMEATE (perfusion with multiple echoes
and temporal enhancement) sequence described previously in [16], extended by a 180◦ refocusing pulse
and additional EPI readout trains to measure both GE and SE data.
A schematic overview of a SAGE sequence is illustrated in Figure 2.12.
Figure 2.12: Schematic representation of SAGE EPI sequence. After a 90◦ excitation pulse, two gradient-echo are applied each
at a certain TE. A 180◦ refocusing pulse is then applied, followed by two more gradient-echos and the final spin-echo. Adapted
from [17].
2.4.5.1 SAGE EPIK or GESE EPIK
However, the SAGE-EPI approach also has the usual limitations such as susceptibility artefacts and
geometric distortions resulting from the single-shot EPI readout. Therefore, an alternative method for
GESE-EPI using EPIK was proposed in [53]. This method showed improvements in the perfusion mea-
surements, having a reasonable trade-off between spatial/temporal resolution and brain coverage. SAGE-
EPIK maintains the same sequence design as SAGE-EPI. The only difference is the applications of the
Keyhole technique with and interleaved sampling multi-shot EPI. Instead of using EPI trains to generate
the gradient echoes, EPIK trains are applied, taking advantage of the benefits of keyhole technique, as
shown in Figure 2.13.
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Figure 2.13: Schematic representation of SAGE EPIK sequence. Similarly to SAGE EPI with the difference of taking advantage
of keyhole technique. Adapted from [17].
2.5 Hybrid Imaging
Historically, medical devices, used to image either anatomical structure or functional processes, have
been developed somewhat along independent paths. CT, PET and MRI are the main techniques used
in brain studies. CT provides anatomical information, PET provides functional/metabolic information,
meanwhile MRI provides anatomical and functional/metabolic information. However, the recognition
that combining images from different techniques can nevertheless offer significant diagnostic advantages
gave rise to hybrid imaging techniques.
Hybrid imaging is a term used to refer to the combination of two, or more, imaging modalities to form a
new technique, in order to overcome some of the existing drawbacks of the individual modalities. MR-
PET is a example of this combination, and was used in this study, therefore further information is given
in the following subsection.
2.5.1 MR-PET
MRI is a imaging technique that has been deeply described throughout this chapter, both in terms of
the theoretical principles behind it and mainly used hardware, but different sequence schemes were also
approached.
Positron-emission tomography (PET) is, very briefly, a powerful nuclear medicine imaging technique
that can be used to measure metabolic activity or body function processes in vivo. The system detects
pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the
body on a biologically active molecule called a radioactive tracer and decays throughout time. Three-
dimensional images of tracer concentration within the body are then constructed by computer analysis.
In summary, PET imaging provides information about tracer uptake revealing information about the tu-
mor activity.
Each of these imaging procedures, has its own advantages and drawbacks. Combining imaging modal-
ities to use their strengths together and to compensate for their weaknesses has been a major asset in
combined modalities. For these reasons, and following the success of combined PET-CT, in recent years,
several research groups have re-addressed the applications of and developed combined PET-MRI sys-
tems. To be of notice that the first PET-MR devices were built even before the introduction of PET-CT
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[47][48]. However, several technical difficulties made the combination of these two modalities challeng-
ing and the first integrated system study of the human brain was only published in 2008 [49].
For brain studies, the combination of MR and PET addressed some of the existing limitations of each
technique in addition to improving pathologies’ diagnostic. While MR imaging allows the differentia-
tion between healthy and unhealthy tissues in most brain regions with normal cells, PET has the unique
capability of directly showing metabolism to a cellular level resultant from tracing the tracer uptake.
Hereupon, by combining both techniques more information can be easily assessed comparing with MRI






A brain tumor consists of a tissue mass formed by an abnormal growth of brain cells. A healthy cell
usually ages and eventually dies, being replaced by an equal one. However, sometimes these cells mutate
and the organism is not able to remove them, allowing them to grow and replicate, forming what is
considered as a tumor mass. These mutated cells function differently from the normal cells. If a brain
tumor is composed of neuroglia cells and fibers, it is called a glioma. These cells provide support to the
neurons and are responsible for their protection and nutrition. 30% of all brain tumors are gliomas.
There are mainly two types of tumors: benign and malignant tumors. Benign tumors are typically
localized, not invading nearby tissue, and do not spread to other parts of the body. Usually these tumors
respond well to treatment. Malignant tumors, however, have infiltrated the nearby tissue, are often
resistant to treatment, may spread to other parts of the body and sometimes recur after being removed
[50].
As a tumor grows to a few mm3 in volume, it will reach a point in time where it can no longer rely on
the passive diffusion of metabolites from the blood vessels to continue its development [51]. For that
new blood vessels must be generated in a process known as angiogenesis [52]. These newly developed
vessels are, in comparison with mature blood vessels, leaky, fragile and incompletely formed. These
differences can be exploited to indirectly characterize the state and grade of the tumor.
Several studies, are also investigating if the tumors can change the brain-blood barrier (BBB) integrity
and functionality [53]. The BBB is a highly selective semipermeable membrane barrier that separates
the circulating blood from the brain and extracellular fluid in the Central Nervous System (CNS). This
barrier allows the passage of water, some gases and other molecules crucial to neural function, while
preventing the entry of harmful substances. Despite what was first believed, tumors only change the
integrity of the BBB, not its functionality.
For CNS tumors, perfusion MRI techniques are more used since they allow quantification of specific
parameters and more accurate tumor grading and differentiation between healthy and tumor tissue.
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3.1 Classification and Grading
Over the past century, tumor classification has been mainly performed according to the tumor histology.
In other words, tumors are classified depending on its microscopic features such as vascularization,
presence of certain proteins, etc. Studies over the past two decades have clarified that other factors should
be taken into consideration when grading the tumor, such as tumor genetics, prognostic to treatment,
tumor anatomic structure, among others ([7], [8], [9], [54]).
In pathology, grading tumor is a matter of how different from the original healthy tissue, the tumor
tissue appears. According to the classification of the World Health Organization (WHO), it is possible to
grade the gliomas on a scale from I to IV, being I the lowest grade and IV the highest. Grade I and II are
associated with low malignancy rate, and are often referred to as low grade gliomas (LGG). Analogously,
grade III and IV refer to higher malignancy, being often addressed as high grade gliomas (HGG) [55].
The diagnosis, grading and classification of tumors has benefited considerably from the development of
MRI which is now essential to the adequate clinical management of many tumor types. The ability of
MRI to not only image the tumor but also demonstrate its morphology and the relationships of malignant
lesions to neighboring structures provide essential medical information. When referring to brain tumors,
conventional MRI is able to provide detailed anatomic images of the CNS tumor. However, grading
and evaluating the malignant potential of a CNS tumor with conventional MRI has been less successful,
in particular, due to factors such as T1 and T2 relaxation times, related to tumor angiogenesis and the
integrity of the blood-brain barrier of neoplastic tissue, being only moderately specific indicators of
malignancy. Meanwhile, PET using biologically active molecules labelled with short-lived positron-
emitting isotopes at micromolar or nanomolar concentrations is one of the most promising techniques
for the imaging of specific molecular processes in vivo. Molecular imaging using PET may provide
relevant additional information on tumour metabolism, and may also be helpful in clinical decision-
making, especially in patients with equivocal MRI findings. In particular, the clinical value of 18F-
FET PET for the identification of tumour relapse has been demonstrated in numerous studies including




The delivery of oxygen and nutrients to the tissue by means of blood flow is commonly known as perfu-
sion.
Perfusion MRI is a term used to refer to a variety of MRI techniques that give insight on the parameters
of cerebral microvascularization: regional blood volume, mean transit time, regional blood flow, etc. The
ability of perfusion MRI to provide information on these parameters has led to these sequences being
used routinely for an increasing number of indications, including tumor imaging, cerebrovascular disease
and more. Therefore, the development of acquisition methods with higher resolution, higher speed and
less artifacts is of interest for the all medical community [59].
Perfusion MRI works around the Fick’s Principle, which derives from the conservation of mass, and
states that the blood flow, BF, to an organ can be calculated using a marker substance if we know the
concentration of the marker taken by the organ, CT(t), the concentration in the arterial blood supplying
the organ, CA(t), and the concentration in the venous blood leaving the organ, CV(t). The Fick’s Principle
can be represented by Equation 4.1.
dCT (t)
dt
= BF · [CA (t)−CV (t)] (4.1)
Perfusion MRI techniques are classified on whether they involve the usage of an exogenous contrast
or not. On one hand, bolus methods, like DSC and DCE, with injection of a contrast agent, provide
better sensitivity with higher spatial resolution and are more widely used in clinical applications. On
the other hand, Arterial Spin Labeling methods allow a completely non-invasive measurement of blood
flow while exploiting an endogenous contrast and have better accuracy for quantification. The difference
between the two first techniques relies on the evaluation of T1 changes, the so-called dynamic contrast
enhancement (DCE), or to observe changes in T2 and T2∗ susceptibility due to paramagnetic Gd3+ ions,
the so-called dynamic susceptibility contrast (DSC). Because the purpose of this work focuses around




Dynamic susceptibility contrast MRI (DSC) is one of the exogenous contrast perfusion imaging methods.
It relies on the injection of a paramagnetic contrast agent, typically Gadolinium-based accompanied by
rapid measurement, using fast imaging techniques, of the transient signal changes during the passage of
the bolus through the brain-also known as Bolus Tracking.
4.1.1 DSC-MRI Data Acquisition
In a typical DSC-MRI imaging session, especially in tumor studies, a preload injection of about a quarter
of the contrast agent is administered to reduce T1 leakage effects on the actual measurements. After a
short period of time, around 5 minutes, the rest of the contrast agent is injected and rapid T2- or T2*-
weighted images are obtained over the entire brain or a section of it. The standard sequence used in DSC
is the single echo, single shot EPI due to its fast temporal resolution.
After the contrast agent’s injection, the hemodynamic signal of DSC will depend on the T2 and T2∗
relaxation times. The contrast agent will mainly stay within the vascular space and, as the CA is a
paramagnetic material, it will distort the magnetic field and reduce T2 around the vessels due to an







, where R20∗ is the intrinsic gradient-echo transverse relaxation rate on the brain tissue without the
contrast agent, r2∗ is the transverse relaxivity of the contrast agent, which depends on the blood volume
and vascular morphology, and Cb is the intravascular blood concentration of the contrast agent. This
relationship can also be applied in a spin-echo sequence as:
R2 = R20 + r2 ·Cb (4.3)
The signal S measured over time t from DSC using a gradient echo-based sequence can be described by:
S(t) = M0sin(α) ·
 1− e(− T RT1(t))




 · e(− T ET2∗(t)) (4.4)
,where M0 is proportional to the equilibrium magnetization and α is the flip angle used in imaging. In
order to measure the changes that occur in T2∗ , all acquired data are compared to a baseline signal at










, where SB represents the signal from the baseline. This corresponds to a time interval where there
is no contrast agent detection, yet. Lastly, the most technically demanding portion of the acquisition
process in DSC-MRI is acquiring an estimate concentration of the contrast agent in the blood plasma
as a function of time, Cp(t), the AIF. This function is required to perform nearly all currently available
25
4.1 DSC-MRI
analysis methods. The AIF can be estimated in three different ways. One approach involves introducing
an arterial catheter into the subject and sampling blood during the scanning process for later analysis
[60]. A second method assumes that the AIF is similar for all subjects and averages some AIF’s from
previous subjects to generate an averaged AIF usable for all subsequent studies [61]. A third method
obtains the AIF from the MRI data-sets themselves [62].
4.1.1.1 DSC-MRI Data Analysis
With all acquired data, DSC-MRI parameters can now be estimated. The T2 and the T2* changes mea-
sured through the acquisition time can be assessed in two different ways: a direct analysis of the signal
curves originated from each voxel through time, or full quantification of the contrast agents concentration
change and fitting of the data to a kinetic model in order to derive quantifying parameters. Each method
has its disadvantages and advantages and must be picked according to the study’s objective.
4.1.1.2 Non-parametric Approaches
With few, or even, any computational analysis, it is possible to extract semi-quantitative perfusion pa-
rameters from the intensity curve of the acquired signal data. These parameters are relatively easy to
calculate and useful when fast and no in-depth analysis is required. However, this analysis is not very
precise and lacks consistency. Some semi-quantitative DSC-MRI perfusion parameters are represented
in Figure 4.1 and defined in Table 4.1.
Figure 4.1: DSC-MRI signal curve with representation of semi-quantitative perfusion parameters. Adapted from [63].
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Table 4.1: Nonparametric values of DSC-MRI.
AT or T0
Arrival Time is the first interval between intravenous contrast injection and its
first detection in tissue or a large artery.
TTP
Time to Peak corresponds to the time the intensity curve takes to reach its peak of
signal loss within the organ of interest .
NEI or AUC
Negative Enhancement Integral or Area Under the Curve reflects the total amount
of contrast transiting through the regional vascular system.
MTE
Mean Transit to Enhance reflects the average time for all injected contrast to pass
through the tissue region.
PBP
Percent Baseline at Peak is the ratio between signal intensity at minimum peak
with its baseline values.
PSR
Percent Signal Recovery is the ratio between signal intensity during the
re-circulation phase with its baseline value.
4.1.1.3 Parametric Approaches
To fully quantify perfusion parameters, a kinetic model must be applied to explain the inherent physiol-
ogy. The most accepted kinetic models used for perfusion quantification rely on the assumption that the
contrast material remains within the vascular space as long as the brain-blood barrier remains intact and
T1 changes after injection are negligible [64]. The fraction of injected CA still present in a vasculature





, where h(t) represents the probability density function of transit times. By definition of h(t) as a prob-
ability density function, R(0) is equal to one and R(t) is a positive, decreasing function of time [65].
Consequently, the tissue contrast curve Ct(t) is a relation between the arterial input function (AIF) and
cerebral blood flow (CBF), as represented on
Ct (t) =CBF ·AIF (t)⊗R(t) (4.7)
Cerebral Blood Flow is an important parameter that evaluates the blood’s ability to perfuse brain tissue
adequately in a given time period, representing the instantaneous capillary flow in tissue.
The maximum of CBF · R(t) is usually considered to represent the actual blood flow to the tissue and can
be estimated with knowledge of the AIF and application of the convolution theorem,






, where FT-1 is an inverse of Fourier Transform.
An alternative approach is an algebraic reformulation, derived from the discrete convolution of Equation
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4.7, where the data are sampled at equally spaced time intervals.
c = AIF (CBF · r) (4.9)
, where vector CBF · r contains the unknown discrete flow-scaled residue function.
To obtain the CBF, an alternative approach consists of treating the previous algebraic formulation as an
inverse matrix problem and solve it using singular value decomposition (SVD). SVD decomposed AIF-1
into three matrices, AIF-1=VW-1UT, where V and U are orthogonal and W is a diagonal matrix, whose
inverse is therefore trivial. CBF is then computed from the maximum of:











, where wj are the diagonal elements of W [66].
The Cerebral Blood Volume (CBV) is another important parameter defined as the volume of blood in a
given amount of tissue, being proportional to the total amount of intravascular CA in the tissue. In order










, where kh is a correction factor for the higher erythrocytes concentration in arterial blood than in capillary
blood and ρ is the brain’s density. This correction factor is only used when absolute quantification is
required.
Finally, one last parameter can be calculated. The Mean Transit Time (MTT) is a measure of the main







It has long been of doctors’ interest to acquire blood flow and blood vessels information in order to char-
acterize and diagnose a pathology. In 1927 Egas Moniz introduced cerebral angiography using injection
of a contrast agent combined with traditional radiography. This tool soon became a powerful imaging
technique for the identification, characterization and localization of several medical conditions.
The crescent necessity for imaging techniques to characterize the angiogenic vasculature in drug devel-
opment trials and to study of tumor biology, impulsed by the combination of MRI with angiography, lead
to the establishment of DCE-MRI.
DCE-MRI is one of the exogenous contrast methods based on perfusion imaging methods. It refers to
the acquisition and analysis of MRI data that describes the uptake of an intravenous contrast agent in
regions of interest (ROIs), through evaluation of signal changes related to T1 relaxation time.
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4.2.1 DCE-MRI Data Acquisition
In a typical DCE-MRI imaging session, MR images are collected before, during and after CA injection
into a vein. Each acquired image corresponds to one time point, and each pixel in each image set gives
rise to its own time course which can then be analyzed. A typical DCE-MRI data acquisition requires
three measurements:
1. Recording a map of the native T1 values before contrast administration;
2. Acquisitions of T1-weighted images following CA introduction at a reasonably high temporal
resolution (10-30 second range) to be able to characterize the kinetics of the CA entry and exit into
the tissue;
3. A method to estimate the time rate of change of the concentration of the CA in the blood plasma,
the so-called arterial input function (AIF).
For the first measurement, there are several methods available but the most commonly used is a series of
spoiled gradient-recalled echo images, acquired with different degrees of T1-weighting. Equation 4.13
describes the measured signal intensity for such an image.














, where M0 is a instrument scaling factor, α is the flip angle, TR is the repetition time and TE is the echo
time. The idea is to acquire several images with different flip angles and fit the data to Equation 4.13
with M0 and T1 as floating parameters.
After the acquisition of the T1-map, a series of heavily T1-weighted images must be acquired as the
contrast agent’s is injected. To achieve these T1-weighted images at such a rapid temporal resolution,
compromises in the image quality or tissues range (number of slices) must be made. On the one hand,
the images must be acquired with sufficient temporal resolution to characterize the CA enhancement
characteristic of the tumor under investigation. On the other hand, the images must be acquired with
high enough spatial resolution and coverage in order to image the whole lesion or tumor’s inherent
heterogeneity.
While designing a DCE-MRI data acquisition protocol, one needs to consider the goals of the study and
carefully select the appropriate study parameters balancing the needs of the study with resolution issues.
If a “semi-quantitative” analysis is planned and probing tumor heterogeneity is viewed as important, then
spatial resolution is prioritized. If full quantitative analysis is needed and the CA kinetics need to be well
sampled for accurate model fitting, then high temporal resolution is prioritized.
To satisfy all of these often-conflicted demands, DCE-MRI imaging protocol almost exclusively employs
multi-slice 2D sequences that can be acquired rapidly while allowing for relatively high temporal signal
to noise ratio and spatial resolution.
Similarly to DSC-MRI, perfusion DCE-MRI also requires the measurement or estimation of the AIF for
full quantification of its perfusion parameters. The AIF for DCE can be acquired with the same methods
described before in Section 4.1.1
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4.2.2 DCE-MRI Data Analysis
With all needed data acquired, DCE-MRI parameters can now be estimated. Signal enhancement seen
on the acquired T1-weighted images can be assessed in two ways, as already referred: i) analysis of
signal intensity changes which are so-called “semi-quantitative” or "non-parametric approaches" and
ii) quantification of contrast medium concentration change using pharmacokinetic modeling techniques,
which are so-called "quantitative" or "parametric" approaches. Semi-quantitative parameters describe
tissue signal intensity enhancement using a number of descriptors [67]. Meanwhile, quantitative methods
involve more rigorous theory and modeling and thus, in principle, more accurately reflect physiology than
the semi-quantitative methods. However, quantitative methods, not only are technically more demanding,
but may also not be as reproducible, repeatable, or robust to noise as semi-quantitative methods. With
this and the goals of the study in mind, the proper analysis must be chosen. If only relative changes are
required, then a semi-quantitative approach may suffice.
4.2.2.1 Non-parametric Approaches
The non-parametric dynamic perfusion analyses derive empirical indexes that characterize the shape
and structure of the signal curve, S(t), giving some information related to the underlying physiology of
the tissues. These methods are generally simple and less time consuming as they do not require many
computational steps. In addition, the arterial input function, AIF, is also not required. However, as
these analyses methods are directly based on the signal curve, the resulting information can be influ-
enced by differences in MRI acquisitions parameters or/and scanner types. Although, as stated before,
these methodologies cannot derive physiological information, e.g.vascular permeability and blood flow,
directly from the S(t); there is a correlation between the curve-related measurements and the implicit
system’s biology.
Figure 4.2: DCE-MRI signal curve with representation of semi-quantitative perfusion parameters. Adapted from [68].
These perfusion related measurements are defined in Table 4.2 and some are represented in Figure 4.2.
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Table 4.2: Non-parametric values of DCE-MRI. Adapted from [69].
AT or T0
the onset (lag or bolus arrival) time of an enhancement curve i.e. the time from the CA
injection to the appearance of contrast in the tissues.
ME
Maxt S(t)-the maximum signal intensity (peak enhancement) of a given time-varying
signal S(t).
MEa
ME-S0-the peak maximal absolute enhancement of a given signal S(t), i.e., the
difference between Sm and baseline (S0) intensities.
ME
S0
the relative signal intensity (RSI) or peak enhancement ratio (PER), i.e., the relative
peak enhancement.
TTP
the time-to-peak, i.e., the time before the CA reaches its highest value in the tissue
during the first-pass cycle.
T90 the time before the CA in the tissue reaches 90% of the maximal signal intensity
ME
T T P
the maximum intensity time ratio (MITR), i.e., the ratio between the peak
enhancement ME and the time-to-peak TTP
ME
(T T P−T 0)
the wash-in slope (the maximal or initial upslope), i.e., the slope of the line connecting
S0 and Sm points.
(Smax−Sfinal)
(T max−T T P)
the wash-out slope (down-slope), i.e., the slope of the line connecting Sm and the last
point of the signal curve S_final.
(SE−S0)
(SL−S0)
the signal enhancement ratio (SER) is the ratio of early to late contrast enhancement;
where SE and SL are the early and late contrast signal intensities measured at
predefined times of TE and TL, respectively.
4.2.2.2 Parametric Approaches
Parametric or quantitative hemodynamic indices of DCE-MRI data can be derived with physiological ba-
sics as they are intimately related to the study of the pharmacokinetics of the contrast agent, particularly
their contributions within and elimination from the blood [70]. These approaches, aim to estimate kinetic
parameters by fitting the acquired data into models that explain the underlying physiology while making
some assumptions. There are several models available, differing in the assumptions and simplifications
made and the choice of a particular model for perfusion quantification depends on many factors, such
as imaged area, tissue’s properties, whether the image volume allows for AIF determination, temporal
resolution, and many other.
The parametric kinetic models can be categorized in compartmental models or spatially distributed ki-
netic models based on whether they assume the existing tissues to be a finite number of interacting
homogeneous compartments or assume the compartments to be infinitesimal. The principal assumption
is that the human body can be represented by one or more “compartments” into and out of which the
contrast agent dynamically flows. Another assumption is that in each compartment the CA is uniformly
distributed throughout the volume.
Well-known compartmental models are based on the principles of the Kety’s model [62]. Usually, a two-
compartment model is used as it is more realistic. These models consider the intravascular extracellular
volume fraction to be the central compartment (vp), also referred as blood plasma, and the extravascular-
extracellular volume fraction to be the peripheral compartment (ve) as depicted in Figure 4.3.
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Figure 4.3: General representation of a two-compartment model used to describe the inherent physiology for perfusion param-
eter derivation. Adapted from [69].
In this model, the CA is introduced into the blood plasma by Ca(t), yielding a dynamic concentration
Cp(t) in the first compartment. The CA will then diffuse into the extravascular-extracellular space (EES)
in a reversible process characterized by a distribution rate constant (k12) and a redistribution rate constant
(k21). The CA is eliminated in an irreversible process described by the rate constant kel. Since, the
parameters k12 and k21 control the CA transfer from the blood plasma to the tissue, they are related to
capillary permeability. The total tissue concentration, Ct(t), is described by:
Ct(t) = vpCp + veCe(t) (4.14)
, where vp and ve are the fractional plasma and EES volumes respectively, both with values between
0 and 1. One of the most common compartmental models and widely used in Brain Perfusion MRI
quantification is the Tofts model and is described in detail below.
Tofts Model
The Tofts compartmental model was first proposed by [71] and unified many previous models while also
introducing common characteristic parameters and naming conventions.
This model assumes that the contrast agent diffuses from and returns to the blood plasma at rates depen-
dent on the forward transfer constant, ktrans (min-1) and the reverse constant , kep (min-1), as represented
in Figure 4.4. It is considered a one-compartment model for weakly vascularized tissues as it ignores
the intravascular compartment: vp= 0. However nowadays, it is often applied in situations where the
condition vp≈ 0 is not necessarily fulfilled, for example in tumor scenarios, but where the data quality is
inadequate to resolve any additional structure.
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Figure 4.4: Schematic representation of the CA transfer in the Tofts model between the intravascular space and the EES space.
Adapted from [69].
As the intravascular space volume contribution is ignored, the general equation to express the changes in
the concentration of CA in the tissue is:
dCt
dt







, where kep = Ktrans/ve. The CA concentration in the plasma, Cp(t), after the injection specifies the AIF
and is used as the initial condition to estimate Ct(t). Therefore, at t=0, both concentrations are 0 and the






Physiologically, Ktrans is the most important and significant tissue dependent parameter in the Tofts
model. It assesses either plasma flow in flow-limited scenarios or tissue permeability in permeability-
limited scenarios for the uptake. In mixed scenarios, it indicates a combination of the flow and perme-




The main focus of this work is to acquire both DSC and DCE data using SAGE EPIK, and quantify both
data-sets to obtain perfusion parameters specific to each technique. In this chapter, the reader is presented
with the materials and methods used throughout this study in order to complete the proposed goals. A
brief description of the used data, equipment and acquisition protocol will be included, in addition to the
image processing and data analysis description.
5.1 PET-MRI Scanner
All PET-MRI acquisitions of this project were performed at a bimodal scanner Siemens 3T hybrid
MR/PET scanner at the FZJ INM-4 institute, allowing the simultaneous acquisition of MR and PET
data. This hybrid scanner is a MAGNETOM TIM Trio System with an integrated Siemens BrainPET
insert of high resolution, located inside of the MR bore and fixed with an air cushion 5.1.
Figure 5.1: Forchungszentrum Juelich, INM-4 institute, 3TMR-BrainPET hybrid scanner for brain studies.
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5.2 Datasets and Acquisition
5.2.1 Patients
Twenty-two patients with suspected brain tumor, recurrent tumor, or who required imaging of tumor stage
progress were recruited for this study. Some patients were receiving or received radiotherapy, others had
brain surgery for tumor removal, however this was considered not relevant for this study’s outcome.
Out of these twenty-two, fifteen patients (seven females and eight males) were fully diagnosed with a
brain tumor and the resultant data sets were used in this study. Further information about the patients
can be found in Appendix 7.1. If tumor histology was available, tumors were graded accordingly to the
guidelines suggested by the World Health Organization (WHO) [55]. However, this information was
generally not present, as it requires a biopsy. After a complete description of the study, written informed
consent was obtained prior to scanning.
5.2.2 MRI acquisitions
An inversion recovery EPIK sequence, previous to contrast injection, for T1-mapping was performed.
For this sequence a repetition-time of 60 ms, a flip-angle of 25◦ and a echo-time of 25 ms were used for
63 time points. Thirteen slices with a matrix size of 96×96 were acquired.
Following contrast injection, perfusion weighted images were acquired using the combined 5-echo GESE
EPIK sequence with a SPARSE factor of 3, described in the Section 2.4.5. A 90 degree pulse was
applied, succeeded by two gradient echoes with the echo-times of 12 ms and 28 ms, respectively. Next, a
refocusing pulse of 180 degrees followed by the two remaining gradient echoes and the spin-echo, with
the echo-time of 54 ms, 70 ms and 85 ms, respectively. For this sequence, repetition-time was set to 1500
ms and 13 slices with a thickness of 3mm were acquired with a matrix size of 96×96, parallel imaging
acceleration (R=2), partial Fourier= 5/8 and a field of view of 240 mm. For better understanding, a
protocol scheme was included in Figure 5.2.
For each one of the twenty-two subjects, Gadoteric acid (Dotarem Guerbet) was injected with a dose of
0.1 mmol/Kg of body weight and 100 volumes were acquired in order to track dynamic signal changes
induced by the contrast agent. Injection was performed automatically with a power injector (Injektron
82 MRT Medtron AG) at a flow rate of 5 ml/s.
Figure 5.2: Scheme of imaging protocol.
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5.2.3 PET acquisitions
Simultaneously with the MR measurements, a 18F-FET PET scan was carried out in the hybrid scanner.
For that, an intravenous injection of 3 MBq of 18F-FET/kg was injected [72]. PET data were recon-
structed using ordinary Poisson-OSEM 3D ([73]) algorithm with 4 subsets, 15 frames with 60 seconds
each and 32 iterations. The reconstructed images have an isotropic voxel size of 1.25 mm3 with a matrix
size of 256×256×153. In addition, all images were post processed using a 3D Gaussian filter and motion
corrected with the aid of "Pmod" software [74]. Note that, the BrainPET is a head only high-resolution
PET insert with an isotropic centre resolution of 3 mm [75].
5.3 Post processing and analysis
The MRI data was analyzed using MATLAB v.2017 and v.2015a (The MathWorks, Inc, USA) [76] with
the addition of the function fitdcemri [77] and in-house developed scripts. The PET data was visualized
using the Amide’s a Medical Image Data Examiner (AMIDE) [78].
The acquired and processed PET images were used for confirmation of existent tumor in the patient. If




The concentration-time curves in DSC-MRI are generated based on an assumed linear relationship be-
tween the contrast agent and the change in the apparent transverse relaxation rate by the first passage of







,where k2 is a constant dependent on the transverse relaxivity, field strength, pulse sequence, vascular
morphology and the contrast agent composition [79]. For the injected contrast, k2 has a value of 4.9
L/mmol-s at 3 T [80].
The signal, S, measured over time, t, from DSC-MRI using a gradient echo-based sequence can be





















∗, a similar equation is obtained where S(t) no longer represents all the signal
throughout the acquisition time, Equation 5.3. It represents only the data before the contrast detection in
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The obtained equation 5.4 shows the potential effects of T1 relaxation on the concentration curve. If the
BBB remains intact, one can assume the contrast agent to remain within the blood vessels, no extravasa-
tion occurs and the T1 is equal through time. This leads to the simplified equation 4.5.
For the first gradient echo (TE=12 ms), the concentration curve was calculated using equation 5.1, where
∆R2* results from equation 5.4.
However, since the tumors actually tend to disrupt the BBB, it is of high relevance to quantify the con-
trast agent concentration while taking into account the extravasation effects resultant from this disruption.
Multi-echo acquisition methods are quite useful for this purpose, as the ratio between two signal curves
of different echo times allows for the desired quantification without any over assumptions. From equation
4.4, the signal for the 1st and 2nd echo are:
ST E1(t) = M0sin(α) ·
 1− e(− T RT1(t))




 · e(− T E1T2∗(t)) (5.5)
and









 · e(− T E2T2∗(t)) (5.6)













5.3 Post processing and analysis
The pre-contrast apparent transverse relaxation, T20
∗, rate is similarly calculated. Again, adjusting equa-












This expression was used to calculate the concentration curves with T1 leakage correction.
In parallel, one could alternatively calculate the concentration curves using the spin-echo data where a
linear relationship between the contrast agent and the change in transverse relaxation rate by the passage







,where k2 is a constant dependent on the transverse relaxivity, field strength, pulse sequence, vascular
morphology and the contrast agent composition [79]. For the injected contrast, k2 has a value of 4.9
L/mmol-s at 3 T [80]. For a spin-echo MRI sequence, with a flip angle of 90◦ the signal equation is:











,where M0 is proportional to the equilibrium magnetization and α is the flip angle used in imaging. In
order to measure the changes that occur in T2 , all acquired data are compared to a baseline signal at time










Based on a multi-echo DSC sequence and considering that the contrast changes are slower than the time
scale of T1, the spin-lattice changes can also be obtained [81].
To obtain a T1 weighted signal, the signals from the first two echoes can be combined by extrapolating
the data to zero echo time (TE=0)









, where S0 will correspond to a set of images with the same parameters as the resultant from the MRI
sequence, but influenced by T1 changes only. This way, T1 leakage correction can be performed also for














Due to the fact that the previously described method only makes use of two of the five echoes in the
GESE-EPIK sequence, another approach to calculate the R2 and R2* was applied. This approach aims to
better estimate the R2 and R2* by using a nonlinear least squares fitting to a piecewise function (equation
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2) ,T E5/2 < τ < T E5
(5.14)
,where S0I and S0II correspond to the baseline signal. Since a nonlinear fitting takes a lot of computational
memory and time, the equation was transformed into a linear relationship instead. For each point in time,







−T E1 0 1 0
−T E2 0 1 0
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, which can be represented as Y=A × X . The values for R2 and R2* are calculated by X= A-1 × Y. This
method tries to better estimate the concentration curve, considering T2 and T2* effects.
5.3.1.2 Brain Mask
In order to remove unwanted signal data from outside the brain region, a set of brain masks were com-
puted, one mask for each available slice.
As a starting point, a global threshold was found, following Otsu’s method [83] and all values above the
threshold were set to one, under the threshold were set to zero. For every slice, from all five echo data,
a binary mask is created. All the five brain masks from the same slice are, then, combined to originate
only a mask per slice. This method for mask creation was choosen due to its simplicity.
Since the masks are binary, they are easily multiplied to each available data image, reducing them to the
area of interest - the brain.
5.3.1.3 AIF estimation
For the quantification of DSC-MRI parameters, an accurate arterial input function that represents the
concentration of the contrast agent in the blood plasma is of high relevance. Therefore, special attention
must be paid when choosing the method to obtain the AIF [84].
In order to avoid the need of a highly trained staff, reduce subjective errors and decrease the time for AIF
estimation, an automatic method was used.
The chosen method starts by identifying the time-point correspondent to the lowest signal intensity,
tmin, which corresponds to the highest amount of contrast agent in the blood’s plasma. Then, a search
for the image’s voxels where the bolus’ peak occurred before the time-point tmin was performed. The
concentration curves for all the voxels that matched the criteria were obtained and organized by order of
peak intensity, from lowest to highest. The highest five were averaged resulting in a global AIF. A global
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AIF is a term used to refer to one only AIF that is used for all of the existent pixels.
This method was repeated for the concentration curves obtained from the previous section, in order to
compare the T1 leakage correction with the uncorrected version.
5.3.1.4 Parameter Quantification
After defining the required AIF, calculating the concentration curves and obtaining a proper brain mask,
DSC-MRI parameters ought to be calculated.
For each available patient, all parameters were calculated in the three previously described ways with
the only difference being the correction performed on the calculus of the concentration curves and the
correspondent AIF. The cerebral blood volume was computed from equation 4.11 as the ratio between
the area under the curve (AUC) from the concentration curve through time and the AUC of the AIF
through time. Cerebral blood flow was calculated using the maximum of the impulse response function,
represented in equation 4.10 from the circular singular value decomposition (SVD). Additionally, the
mean transit time was computed as the ratio between CBV and CBF, as stipulated in equation 4.12.
5.3.2 DCE-MRI
5.3.2.1 Signal Extrapolation
From Section 5.3.1.1, equation 5.12 allowed the estimation of a set of T1-weighted images used to
correct the leakage effects from BBB disruption of the T2-weighted time curves. Another use of this
extrapolated data would be quantification of DCE-MRI, as this technique requires nothing else but, T1-
weighted images acquired through contrast injection [81].
5.3.2.2 Signal Conversion
Conventional DCE-MRI concentration curves are generated based on a assumed linear relationship be-







,where k1 is a constant dependent on the transverse relaxivity, field strength, pulse sequence, vascular
morphology and the contrast agent composition [79]. For the injected contrast, k1 has a value of 3.5
L/mmol-s at 3 T [80].
The signal, S, measured over time, t, from DCE-MRI using a gradient echo-based sequence can be















5.3 Post processing and analysis
Following the same methodology described for DSC-MRI, an expression for 1/T10 can be obtained,











































This equation 5.19 demonstrates the potential influence of T2* effects on the concentration curves ob-
tained with DCE-MRI. From equation 4.4, assuming fully relaxed spins, M0 can be estimated from a
single-shot, single repetition, in a limit that TR −→ ∞. Equations 5.5 and 5.6 become:











Again, the ratio between these two equations then becomes an expression of T2*(t). Replacing this ratio












,where STE10 and STE20 are , respectively, the first image from the first and second gradient echoes. For
equation 5.19, S(t) becomes the extrapolated data calculated from expression 5.12.
Since the data applied to calculate ∆ R1 results from an extrapolation to TE=0, one can assume that, over













Two different concentration curves were calculated from equation 5.23: one where SB corresponds to the
data acquired from the T1-mapping previous to contrast, and another where SB results from averaging
the first eight time-points of the extrapolated image (baseline signal).
5.3.2.3 Brain Mask
For DCE-MRI analyses, the brain mask obtained from the DSC-MRI data was applied to all DCE-MRI
extrapolated images and data.
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5.3.2.4 AIF estimation
For DCE-MRI analyses, the AIF calculated from the DSC-MRI data and corrected for T1 leakage effects
was used for all parameter quantification analyses.
5.3.2.5 Parameter Quantification
To fully quantify perfusion DCE-MRI parameters, a kinetic model, that represents the physiology of the
inherent tissues and allows for the accurate estimation of perfusion parameters, must be applied to the
data.
Due to its simplicity and general use in brain tumor studies, the Tofts model was selected among the
many kinetic models available. The Tofts model was applied by means of the, already referred, matlab
function fitdcemri. This function required the input of the concentration curve for all pixels, the AIF and
a time vector. As outputs, the function computed the parameters Ktrans and kep and the value R2 which
indicates the degree of proximity of the applied model fitting to the measured real values. The model
was applied 3 times for a differente set of inputs:
1. Concentration curve calculated with usage of T1-mapping previous to contrast and uncorrected
AIF for T1 leakage;
2. Concentration curve calculated with usage of T1-mapping previous to contrast and corrected AIF
for T1 leakage;
3. Concentration curve calculated with usage of only extrapolated data and corrected AIF for T1
leakage;
All models were set to have a R2 higher than 90% to increase the accuracy of the fitted model.
5.3.3 Brain Tumor Analysis
Several DSC- DCE-MRI studies have tried to link the tumor histology or the tumor response to treatment,
with the obtained perfusion parameters. Although not a main objective of this study, if the data were to
be available, investigation on this matter ought to be done.
However, histology reports for all patients were not available, as it involves the invasive acquisition of
a tumor biopsy. Since the tumor type was not known, tumor grading was not possible and, therefore,
further analysis of this matter was not pursued.
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In the following chapter, the obtained results from all performed tests from Chapter 5 and respective
analysis are here presented.
6.1 PET
From the applied imaging protocol, several image data-sets were acquired. As already referred, the
PET images were only used as a filter of patients relevant for the perfusion quantification study. For
example, in Figure 6.1, the patient does not present an activated region with the radio-pharmaceutical
tracer, leading to the deduction that there is no tumor. This patient was not further included in the present
work. Meanwhile, Figure 6.2 depicts an activated region, confirming the existence of the tumor. This
patient data was then fully analyzed and perfusion parameters were derived. From 22 patients, only 15
were selected for this study.
Figure 6.1: 18FET-PET images for a negative tumor patient. No active region is shown.
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Figure 6.2: 18FET-PET images for an identified tumor patient. The tumor is easily identified on the right hemisphere of the
brain.
6.2 DSC-MRI
Resultant from the Multi-Echo GESE-EPIK sequence protocol, 13 slices for 100 time points for 5 echoes
were acquired, i.e. in total, 500 images. In Figure 6.3, an example of the acquired images, for a random
patient, are shown.
Figure 6.3: GESE EPIK images with GE, GESE and SE contrast. The top row shows the five echoes at the baseline while the
bottom row shows the images at the peak bolus passage.
The top row includes a slice for each of the acquired echoes for a baseline point, while the bottom row
shows the same slice for the peak bolus passage. A small area on the right hemisphere, in the anterior
plane, is enhanced with the contrast agent passage, identifying the tumor region.
Figure 6.4 shows the time curve of the signal intensity depicting the arrival of the contrast agent in a
single, representative gray matter voxel. Despite the unclarity of presented image due to multi-echoes
display with different intensities each, for all echo times it was possible to clearly track the dynamic
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signal changes even though a higher signal drop was found in the earlier echoes compared to the later
ones.
Figure 6.4: Signal intensity time course for the different echoes showing the arrival of the contrast agent.
6.2.1 Signal Conversion
In Section 5.3.1.1, the processes of how acquired data was used to calculate the required concentration
curves were described. From equations 4.5, 5.8 and 5.15, ∆R2* curves were calculated and plotted in
Figure 6.5 (left). To clarify, the curve referred to as matrix corresponds to the result from equation 5.15 ;
equation 5.8 to the curve ∆R2* with leakage correction; and the uncorrected curve to equation 4.5 derived
data.
Figure 6.5: T2*-weighted time course data derived from 5 echoes-matrix; with and without T1 correction are depicted (left).
T2-weighted time course data with and without T1 correction are depicted (right).
T1 leakage effects generally cause an underestimation of the peak bolus and negative values following
the peak curve where one would expect some contrast re-circulation. By analyzing the plotted curves, it
is observed that the uncorrected ∆R2* curve portraits exactly the mentioned leakage effects. Meanwhile,
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the other two curves, accurately demonstrate the applied correction, showcasing the benefits of multi-
echo sequences.
However, if one were to compare the two successful methods, the matrix methods involves more com-
putational power and time which do not justify its further usage in this study where only patients with
well-identifiable tumors are included. Perhaps patients where a higher precision is required, would ben-
efit from this last method.
From equations 5.11, 5.13 ∆R2 curves were calculated and plotted in Figure 6.5 (right). Similarly to
the ∆R2*, the T1 leakage effects were successfully corrected through the usage of equation 5.13. In
opposition to the uncorrected curve, the corrected apparent transverse relaxation rate does not present
negative values, nor was underestimated. Both relaxation rates were rectified, avoiding possible errors in
the parameter quantification, resultant from this component.
6.2.2 Brain Mask
As described in Section 5.3.1.2, a brain mask for each slice was created to remove all signal from outside
of the brain area. An example of the resultant slice can be seen in Figure 6.6. Although some random
pixels from outside the skull were still included, the majority of the unwanted voxels were successfully
unaccounted for.
Brain masks are particularly useful in perfusion MRI quantification as they allow the selection of the
areas of interest for the quantification, removing unnecessary computational time on uninteresting areas.
Figure 6.6: On the left, an image from the first echo. On the right, the respective slice applied mask.
6.2.3 AIF estimation
The arterial input function is a requirement for perfusion quantification in order to accurately determine
the time rate of change of the contrast agent’s concentration in blood plasma. The accuracy of the
AIF significantly influences the precision of the pharmacokinetic parameters extracted. Therefore, the
incorrect estimation of this function has severe consequences in both DSC and DCE-MRI quantification.
If the arterial blood flow is not fully saturated or the T1 leakage effects are uncounted for, this leads to an
overestimation of the AIF [85]. MRI signal amplification or blood flow pulsatility are also factors that
lead to incorrect estimation of the AIF [86], [87].
47
6.2 DSC-MRI
In this work, T1 leakage effects are one of the biggest source of errors. For this reason, it is of high priority
to correct the extravasion of CA leading to incorrect estimation of the AIF. In Figure 6.7 it is shown both
the uncorrected and the corrected version of the AIF. It can be observed that the peak intensity of the
uncorrected curve is more than twice higher than the corrected version. It is concluded that the correction
performed for the AIF was successful, addressing the issue of overestimation.This overestimation would
have led to wrongly quantified parameters, inducing misinterpretation of the patient condition. This is a
strong example of the importance of accounting for T1 effects and overestimation of the AIF.
The influence of the AIF is further studied in the next sections in addition to the effects of CA extravasion.
Figure 6.7: Derived AIF from T2* uncorrected and corrected for T1 leakage effects.
6.2.4 Parameter Quantification
In order to address the real effects of the performed corrections for T1 leakage effects and AIF overesti-
mation, parameters of perfusion DSC-MRI were calculated for both uncorrected and corrected apparent
transverse relaxation rates.
Throughout this section, for a patient, images presenting each quantitative parameter are shown. In the
presented figures, image 1) results from calculating the respective parameter map while using uncor-
rected data, while image 2) results from corrected data usage. By data, it refers to both the ∆R2* curve
and the AIF. In addition, a table including values for the tumor, white and gray matter tissues, from the
same patient, were also included for each of the parameters for a more direct comparison.
All the acquired values and parameters maps were compared with the available literature ([88], [89],[90]).
For healthy tissue, CBF usually has values between 10-100 mL/s/100gr; CBV between 0.1-8 mL/100gr;
and MTT between 0.01-0.3s. For tumor tissue, CBF usually has values between 50-300 mL/s/100gr;
CBV between 2-30 mL/100gr; and MTT between 0.01-0.4s. This comparison with only the literature
had to be performed because another DSC-MRI sequence could not be acquired. Several impediments
lead to the impossibility of another perfusion sequence acquisition. Firstly, each DSC-MRI perfusion se-
quence requires the injection of a contrast agent. If two sequences are acquired then, two bolus injections
would have to be injected into the patient. This adds up to the amount of exogenous contrast that the
kidneys will have to filter. If the patient has a healthy renal system this is already unadvised, moreover if
the patient is elderly and has renal pathologies. Secondly, some studies have warned for the possibility of
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Gadolinium accumulation in the brain tissue or/and bones [91]. More injections, mean further contrast
agent accumulation. Lastly, it requires more acquisition time. Most of the patients in this study were
debilitated and asking for twice the required extra time was not acceptable.
For these main reasons, the results were compared to the literature, as other have done before ([88],
[89],[90]).
Figure 6.8: Cerebral Blood Flow for: 1) uncorrected; 2) corrected for T1 leakage effects.
Table 6.1: CBF values for tumor, gray matter and white matter while using ∆R2* corrected and uncorrected of T1 leakage
effects.
Tumor tissue Gray matter White matter
Uncorrected CBF [mL/s/100g] 153.5 40.31 8.07
Corrected CBF [mL/s/100g] 161.3 77.63 27.97
Figure 6.9: Cerebral Blood Volume for: 1) uncorrected; 2) corrected for T1 leakage effects.
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Table 6.2: CBV values for tumor, gray and white matter while using ∆R2* corrected and uncorrected of T1 leakage effects.
Tumor tissue Gray matter White matter
Uncorrected CBV [mL/100g] 2.0245 0.9626 0.39
Corrected CBV [mL/100g] 20.96 4.737 1.405
Figure 6.10: Mean Transit Time for: 1) uncorrected; 2) corrected for T1 leakage effects.
Table 6.3: MTT values for tumor, gray matter and white matter while using ∆R2* corrected and uncorrected of T1 leakage
effects.
Tumor tissue Gray matter White matter
Uncorrected MTT [s] 0.0132 0.0239 0.0483
Corrected MTT [s] 0.1299 0.0610 0.0502
For all three parameters, the influence of T1 effects is clear by observing Figures 6.8, 6.9 and 6.10. The
tumor, by disrupting the BBB, increases the amount of CA leaking into the EES of the tumor tissue,
which unaccounted for, leads to the underestimation of the perfusion parameters. By comparing images
1) with 2) of all parameters, one can see a better delimitation of the tumor area in 2) where corrections
were applied.
In addition, not only the tumor area was affected by the extravasion of the contrast agent, but also the
gray and white matter tissues. By observing the values in Tables 6.1, 6.2 and 6.3, it is concluded that
both tissues’ perfusion DSC-MRI parameters were underestimated. This is potentially misleading as one
can assume a tumor to be of a lesser severity when evaluating the values from the wrongly calculated
curve without T1 leakage correction. For all patients similar results were obtained and can be accessed
in the created bar graphic for each of the parameters, Figure 6.11 (left), 6.12 (left) and 6.13 (left). An
improvement can be generally seen in CBV, CBF and MTT.
Summing up, all obtained perfusion parameters were in accordance with the available literature and
performed as expected, highlighting the tumor area from the healthy tissue. In addition, the performed
corrections were effective and their importance was confirmed.
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Figure 6.11: For all patients, the graphic presents: CBF values for tumor tissues calculated using corrected and uncorrected
data of T1 leakage effects (left); CBF values for three tissues, calculated using corrected data (right).
Figure 6.12: For all patients, the graphic presents: CBV values for tumor tissues calculated using corrected and uncorrected
data of T1 leakage effects (left); CBV values for three tissues, calculated using corrected data (right).
Figure 6.13: For all patients, the graphic presents: MTT values for tumor tissues calculated using corrected and uncorrected
data of T1 leakage effects (left); MTT values for three tissues, calculated using corrected data (right).
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For each of the parameters, another bar graphic was made, containing, for each patient, values of three
different tissues of interest: tumor, white matter and gray matter tissue. Analyzing the graphics on the
right from Figures 6.11, 6.12 and 6.13 several conclusions can be reached.
Firstly, the bar graphics provided a visual evidence that the tumor tissue always has a higher signal than
healthy tissues. This is resultant from tumor angiogenesis which increases the blood vessels surrounding
the tumor area and, therefore, increases blood flow and blood volume to the area in question, augmenting
the DSC parameters’ values.
Secondly, the white matter values are always the lowest and around the same values. This serves as
strong evidence that the parameters were not randomly calculated, but actually have some ground truth
and correlate well with human physiology.
Thirdly, although at first look the same cannot be said about the gray matter tissue values, one must
consider that the values were not measured from the same brain slice for all patients, as the tumors were
localized in different regions. This slice variation causes differences in the calculation of the gray matter
values, as some regions have more vascularization and a more intense presence of gray matter sulcus
than others, for example the insular cortex.
However, there is still room for improvement, as some errors are still frequent in the analysis of the
data and may have influenced the results. For example, the manual identification and selection of tissue
areas for parameter estimation, might have induced errors by wrongly including voxels of another tissue
through misidentifying the tissue type. Also, the MTT values for tumor tissue did not show any directly
correlation with tumor tissue, having sometimes higher values for tumor tissue than for healthy but also
vice versa.
In essence, full DSC-MRI perfusion quantification for all tumor patients was successfully achieved,




From equation 5.12, an extrapolated signal was calculated accounting only to T1 changes. In addi-
tion to being used for leakage correction, the extrapolated signal was used for DCE-MRI quantification.
However, confirmation that the signal was correctly extrapolated and indeed provided T1-weighted infor-
mation was required. Therefore, a slice from the baseline period and a slice after contrast agent detection
were visualized. In addition, the difference between the two time sets was also calculated and visualized.
As seen in Figure 6.14 (left), the difference between timepoints picture depicts signal enhancement in
the tumor area meanwhile other regions remain dark (∆ = 0). This confirms that the extrapolated signal
registers changes throughout time, validating the usage of this data for DCE quantification.
For further confirmation, the signal versus time graphic was plotted for a selected region of interest in
the tumor area and for a healthy area. In Figure 6.14 (right), the signal differences between tumor and
healthy tissue can be identified. As expected, the tumor tissue has a sudden and high signal increase
resultant from passage of the contrast agent from the blood vessels into the EES of the tumor tissue.
52
6.3 DCE-MRI
Meanwhile, healthy tissue, as there is no BBB disruption in these tissues, does not intake much of the
contrast agent, therefore, its signal remains "constant" throughout time. This behavior was expected, as
in accordance with the literature [54].
Figure 6.14: On the left, images from the extrapolated data for the a baseline timepoint, peak bolus passage timepoint and the
diference between the two timepoints are shown. On the right, T1-weighted time course from extrapolated data for tumor tissue
and healthy tissue.
6.3.2 Signal Conversion
From equation 5.19, ∆ R1 curves were calculated and plotted in Figure 6.15 for tumor tissue. To clarify,
the curve referred to as ∆R1 with T1 mapping corresponds to the result from replacing SB with the data
acquired from the T1-mapping previous to contrast injection in equation 5.19; while ∆ R1 without T1
mapping corresponds to the result from replacing SB with the average baseline signal of the extrapolated
signal itself.
Both curves have the expected behavior and reasonable values. In addition, the curves are similar sharing
the same time of increase and similar maximum value. This is a strong indicator that both methods for
calculating the longitudinal relaxation rate worked effectively.
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Figure 6.15: ∆ R1 time curves with and without the usage of the T1-mapping acquired previous to contrast injection.
6.3.3 Parameter Quantification
To quantify DCE-MRI perfusion parameters, a kinetic model was applied to the extrapolated data. The
Tofts model allows estimation of two perfusion parameters: Ktrans and Kep. Ktrans refers to the flow of
contrast agent into the tissue of interest, from the blood. Kep refers to the flow of contrast agent leaving
the tissue of interest into the vascular system. The blood flow is generally ignored in the Tofts model.
All the acquired values and parameters maps were compared with the available literature [54], [92] and
[93] for the same reason listed previously in Section 6.2.4. For healthy tissue, Ktrans usually has values
between 0.01-0.1 1/s and Kep between 0.01-0.05 1/s. For tumor tissue, Ktrans usually has values between
0.05-0.3 1/s and Kep between 0.05-0.4 1/s.
Similarly to Section 6.2.4, in order to address the real effects of the performed corrections, perfusion
parameters of DCE-MRI were firstly calculated using a longitudinal relaxation rate that made use of the
acquired T1-mapping at the beginning of the acquisition protocol with a) AIF without leakage effects
correction; and b) AIF with corrections.
In addition, a table including values for the tumor, white matter and gray matter tissues, from the same
patient, were also included for each of the parameters, to provide a more direct comparison between the
tissues actual values.
The importance of the leakage effects correction and precise AIF estimation are, again, emphasized with
the shown results in Figure 6.16 and 6.17, and Tables 6.4 and 6.5. A wrongly estimated AIF, leads to
parameter underestimation. Although in DCE-MRI leakage effects are not a direct source of error, since
the AIF was estimated from ∆ R2* curves which need to account for this error source, indirectly contrast
agent extravasion becomes a possible source of error. In Figure 6.18, both graphics exhibit the described
effects for both parameters in all patients.
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Figure 6.16: Ktrans resultant from model using a) uncorrected AIF b) corrected AIF for T1 leakage effects.
Table 6.4: Ktrans values for tumor, gray matter and white matter while using AIF corrected and uncorrected of T1 leakage
effects.
Tumor tissue Gray matter White matter
Uncorrected Ktrans [1/s] 0.1719 0.0479 0.0246
Corrected Ktrans [1/s] 0.3327 0.0433 0.0231
Figure 6.17: Kep resultant from model using a) uncorrected AIF b) corrected AIF for T1 leakage effects.
Table 6.5: Kep values for tumor, gray matter and white matter while using AIF corrected and uncorrected of T1 leakage effects.
Tumor tissue Gray matter White matter
Uncorrected Kep [1/s] 0.0184 0.0205 0.0117
Corrected Kep [1/s] 0.05223 0.0409 0.0191
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Figure 6.18: For all patients, the graphic presents Ktrans (left) and Kep (right) values for tumor tissues calculated using corrected
and uncorrected data of T1 leakage effects (left).
Next, to compare the two different methods used to calculate the ∆R1 curves, images of each of the meth-
ods’ results were provided. To clarify, image 1) results from the use of ∆R1 where SB was replaced with
data acquired from the T1-mapping previous to contrast injection in equation 5.19; while 2) results from
the of ∆R1 where SB was replaced with the baseline signal of the extrapolated signal itself. A table with
values of Ktrans and Kep for tumor, gray matter and white matter tissues were also included following the
respective parameters maps.
As shown in Figure 6.19 and in Table 6.4, both methods outputted similar values for all three tissue types.
In both methods, the tumor region is also well delimited and highlighted. This is as expected of tumor
tissue since, due to angiogenesis, the BBB is disrupted in this area increasing contrast agent influx to the
EES of the tumor, justifying the increase in Ktrans.
Meanwhile, the Kep parameter maps do not appear similar. On the contrary, while in method 1) the
tumor area is bright, in method 2) the signal is dark and the brain structures are unclear. Despite similar
values presented in Table 6.7 , it is unclear why the dissimilarities between the two images are observed
in Figure 6.20. Thinking of the parameter definition, one would expect it to be the opposite of Ktrans,
therefore, the tumor region should be dark while the remaining regions ought to continue having mid
range values. From a anatomical point of view, if the tissue in question does not intake any contrast then
there is no contrast to leave the tissue, justifying the low values for healthy tissues. However, if the tissue
allowed the passage of contrast agent into itself, these molecules will not remain inside it forever, as they
ought to be excreted through the kidneys. This would make Kep value as high as Ktrans. It seems that this
parameter interpretation is not set in stone and, therefore, there is no clarity of what should be expected
and which conclusions to draw.
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Figure 6.19: Ktrans resultant from model using 1) T1-mapping previous to contrast 2) extrapolated baseline signal.
Table 6.6: Ktrans values for tumor, gray matter and white matter for method 1) and method 2).
Tumor tissue Gray matter White matter
Method 1) Ktrans [1/s] 0.3327 0.0433 0.0231
Method 2) Ktrans [1/s] 0.2962 0.0519 0.0272
Figure 6.20: Kep resultant from model using 1) T1-mapping previous to contrast 2) extrapolated baseline signal.
Table 6.7: Kep values for tumor, gray matter and white matter for method 1) and method 2).
Tumor tissue Gray matter White matter
Method 1) Kep [1/s] 0.05223 0.0409 0.0191
Method 2) Kep [1/s] 0.0708 0.0425 0.0287
For further analysis, bar graphics for each of the parameters were plotted, presenting the values for
tumor, gray matter and white matter tissues of each patient. From analyzing Figure 6.21 and 6.22, it is
concluded that the values from one method and the other are similar, but no more can be deduced.
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Figure 6.21: For all patients, the graphic presents Ktrans values for three tissues: calculated using T1-map acquired separately
(left); calculated using the baseline signal from the data itself (right).
Figure 6.22: For all patients, the graphic presents Kep values for three tissues: calculated using T1-map acquired separately
(left); calculated using the baseline signal from the data itself (right).
A possible source of error seems to lie in the interpretation of the models outputs. The outputs labeling
seems to have generated some confusion and has led to a common misconception that the Tofts model
describes tissues where the permeability for influx and outflux of contrast agent is different. This is
incorrect. The permeability in all underlying models is symmetric. Several studies have reached a
conclusion that, although there is some truth to the Ktrans values, Kep was introduced in the literature for
notational convenience, and does not seem to have a clear physiological interpretation. In conclusion,
DCE parameters have yet to become fully quantified as each study uses different sequences and applies
different models, influencing the output of the results. Furthermore, each model tries to explain the






Conclusion and Future Work
Simultaneous to the 18F-FET PET protocol, MRI acquisitions were performed taking advantage of the
long exam time required for PET scans. This multi-modality makes the best usage of the patients time,
while providing complementary information about his or hers condition. 18F-FET PET images are ex-
tremely useful for confirmation of tumor presence and visual localization. While the PET images are
acquired, several MRI sequence protocols can be acquired at the same time, without interference.
In this work, a T1 recovery EPIK sequence and a SAGE-EPIK sequence simultaneous to contrast injec-
tion, were inserted in the protocol for brain tumor patients, in the Brain-PET scanner of the Forschungszen-
trum. Both sequences were set to output thirteen slices with a matrix size of 96×96. For each echo, 100
time points were scanned to measure time changes with a temporal resolution of 1.5 seconds.
As previously reported in [41], the estimated T1 values from EPIK were comparable to those from other
T1-mapping sequences, correctly estimating the T1 of white matter and gray matter tissues, reassuring
its use for DCE-MRI perfusion quantification. Although several more slices could have been acquired,
only thirteen were measured in order to match with the slices acquired from SAGE-EPIK.
In order to address some of the existing drawbacks and to carry a more thorough and accurate tumor
investigation with perfusion parameters, the SAGE-EPI sequence method has been addressed in several
studies[17], [94] and [95]. In this study, SAGE-EPIK was used, which in comparison to SAGE-EPI, pro-
vides significantly more brain coverage, better temporal resolution, shorter echo times and higher SNR
for each echo, better spatial resolution and higher immunity to susceptibility artifacts. Furthermore, the
multi-echo capability allows computation of T1-corrected time series data that remove the need for a
pre-bolus injection to correct for leakage effects. This is of great relevance in tumor studies, as tumor
regions suffer from BBB disruption. In addition, this also allows the reduction of measurement time or
the introduction of new sequences in the protocol.
The utilized SAGE-EPIK sequence consisted in the application of 5 echoes in its protocol: four gradient
echos, with a refocusing pulse inbetween, and finally a spin-echo. Several studies only applied three
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echoes, and stated that this is a simplified version that still provides the same information and allows
leakage corrections. However, this simplified version, without the two last gradient echoes, is not less
time consuming than the five echo sequence. As the SE inversion pulse is applied, before the readout
pulse there is a big waiting time window required. SAGE merely takes advantage of this empty time and
inserts two gradient echo pulses for further image acquisition. The main difference between these two
SAGE modalities lies within the calculus method available for estimation of ∆R2* and ∆R2 curve for
parameters estimation.
The parametric images obtained by bolus tracking are influenced by both T1 effects and AIF definition.
To address the contrast agent extravasion, two methods were tested. Both methods successfully corrected
T1 leakage effects.
The first method was proposed by [81] and involved extrapolating the first two echoes to a TE=0, which
accounts only for T1-effects. The other method was a simplified linear fitting version from a non-linear
fitting approach [82]. This method is only applicable if five echoes were acquired. This linear version
reduced a lot of the processing time, but still required more time than the first method, wielding only
slightly better results. Although in this work these small improvements did not justify the higher pro-
cessing time, for studies which require more precision, like lower grade tumors for example, it may
payout to invest in the fitting method. However, the method involving extrapolation to TE=0, also has its
limitations. One drawback is its inability to correct for slice profile mismatch that can occur with spin
echo sequences [17]. While this is important for absolute quantification of T2 values, it is less important
for DSC measurements that rely on assessing changes in R2 for parameter estimation. Moreover, current
SAGE-EPIK implementation quantifies slice profile mismatch during baseline, which is held constant
during the dynamic time course. Thus, the effects of slice profile mismatch are effectively subtracted
when ∆R2 and ∆R2* are obtained for DSC purposes. Since each methods has its inherent advantages
and drawbacks, accordingly to the study’s objectives, the most appropriate method must be chosen. For
this study, the extrapolation method was chosen. Not only was it easier and faster to implement, but
accurately addressed the extravasion effects of contrast agent leakage and the overestimation of the AIF.
The AIF plays a huge role in both DSC and DCE perfusion quantification. Several methods for AIF
determination have been proposed in many studies [84], [96] and [97], but their effectiveness is beyond
the scope of this work. The applied approach for AIF calculation resulted from an in-house developed
code which automatically searches for the best voxels that described the contrast agent delivery to the
brain. In other words, automatically identifies the feeding arteries and from that, computes the AIF. This
automatized process reduces the user induced errors, which would have occurred if a manual selection
of the arteries was implemented for AIF determination.
For both techniques, the influence of the AIF’s corrections and the performed T1 leakage effects’ cor-
rections were investigated. Both were successfully corrected and a relevant difference in the parameters
could be observed. The T1 leakage corrections were the main source of error, inducing huge alterations
in the obtained values. The tumor regions were underestimated and so were the healthy regions. This
could have potentially led to the misdiagnosis of the tumor severeness, inducing a prescription of wrong
treatment. Another scenario would be wrong estimation of the tumor area for surgical insight.
In the AIF estimation, the T1 effects did not have much impact, however some influence was still de-
tected. For the present study the impact in the pathology investigation was not substantial, however if the
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tumors were smaller or of less aggressiveness, this small corrections might have been more impacting
and visible.
With the correction performed, the parameters were then derived. One of the main purposes of this work
was to fully quantify DSC-MRI from the implemented sequence. This objective was fulfilled, as the
obtained values were in accordance with the verified literature. As expected the tumor’s CBF and CBV
values were higher than those of the healthy tissues, due to increase vascularization, from angiogenesis,
and BBB disruption which leads to more permeability and extravasion of nutrients. The MTT parameter
was not directly related to the tumor, sometimes having a higher value while other times the value was
lower. Since it results from the ration of CBV and CBF, and both increase in the presence of tumor tissue,
it is acceptable that the MTT values remains unchanged.
A number of sources of error can affect the parameters calculated from DSC-MRI. In this study not all
were considered and it is possible that they may have affected the obtained results. A possible source of
error lies in the assumption of a linear relationship between the magnetic resonance signals and the con-
trast’s concentration. Actually, the relaxation rate measured inside arteries will vary nonlinearly and thus
the linear assumption can introduce systematic errors for absolute quantification [98]. Another source of
error lies in the dispersion of the bolus in patients with vascular abnormalities, as it tends to get delay
or spread in time [99]. An additional source of error resides in the assumption of an uniform tissue r2
relaxivity, where in reality tissues with different vascularization could have different relaxivities [100].
Despite the possible errors, the results seem reasonable and useful for tumor perfusion analysis.
The other main purpose of this project was to use the extrapolated data from the first two gradient echoes
and achieve full DCE-MRI quantification. The data extrapolation nulls the need for two independent
sequences each requiring contrast injection. Scanning time is reduced and an extra injection is, again,
unnecessary. Full quantification of this technique requires a T1- mapping previous to contrast, obtained
with the EPIK inversion recovery sequence. The effectiveness and accuracy of this sequence had already
been tested before in [40] and [41], and was applied with full confidence in this study. In addition, a
method for DCE-MRI quantification that did not require the acquisition of the T1-mapping, but instead
extrapolated it, was also tested. Both methods outputted similar results, and the obtained values were
in accordance with the available literature. The applied kinetic model for DCE-quantification, the Tofts
model, was chosen for its simplicity and wide use in brain perfusion studies. However only one of the
obtained parameters showed correctness, the Ktrans parameter. Meanwhile the Kep parameter results were
unclear in its meaning and showed some discrepancies. It was searched in the literature, and it seems that
this parameter was introduced in the literature for nomenclature’s convenience, hence it does not have a
clear physiological interpretation [71].
The biggest error source in DCE-MRI is, as observed, the kinetic model. On one hand, simplistic mod-
els introduce systematic errors into the kinetic parameters by overlooking some perfusion physiology
parameters. On the other hand, complex models, include too many variables which cause difficulties in
data acquisition and analyses, making the models almost impossible to apply.
Another source of errors lies, as similarly to DSC-MRI, in the assumption that relaxivity of the contrast
agent is constant for every tissue, when in reality it differs. An additional factor which greatly influences
DCE derived data is the trade-off between temporal and spacial resolution, both required for precise
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model application. In conclusion, there is a lot of room for improvement in full DCE-MRI quantifi-
cation, where model accuracy and precision must be fully investigated to prove its assertiveness with
reality.
Nowadays, several studies have tried correlating the perfusion techniques derived parameters, with the
tumor grade or its response with therapy in order to avoid the need for invasive biopsies. Although not
an objective of this study, if possible it would have been a great addition to the developed work to further
investigate this possible correlation. However, this would require knowledge of the actual tumor grade
or histology which was not available for all patients, and therefore, not further investigated.
Summing up, the main objectives of this study were successfully reached, despite the referred short-
comings. The major source of error of this work lies in the applied kinetic models, both for DSC- and
DCE-MRI. To mitigate this source of error, a more intense and thorough investigation on this matter
must be performed. Not just testing the models, but actually finding a way to measure the real perfusion
values in order to establish the ground truth parameter’s values. The development of a perfusion phantom
would be the main solution for this scenario.
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Figure 7.1: Available information relative to the patients used in this study.
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